["if a patient with early invasive breast carcinoma has er positive, her2-negative, one recommended therapy is tamoxifen + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with early invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is tamoxifen + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with early invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is tamoxifen + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is abemaciclib + anastrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is abemaciclib + anastrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is abemaciclib + anastrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is letrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is letrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is letrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is fulvestrant + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is fulvestrant + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is fulvestrant + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is abemaciclib. therapy type: targeted therapy. therapy strategy: cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is abemaciclib. therapy type: targeted therapy. therapy strategy: cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is abemaciclib. therapy type: targeted therapy. therapy strategy: cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 oncogenic variants, one recommended therapy is abiraterone acetate + niraparib + prednisone. therapy type: hormone therapy + targeted therapy + chemotherapy. therapy strategy: antiandrogen + parp inhibition + corticosteroid. indication: akeega is a combination of niraparib, a poly (adp-ribose) polymerase (parp) inhibitor, and abiraterone acetate, a cyp17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved test for akeega. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 pathogenic variants, one recommended therapy is abiraterone acetate + niraparib + prednisone. therapy type: hormone therapy + targeted therapy + chemotherapy. therapy strategy: antiandrogen + parp inhibition + corticosteroid. indication: akeega is a combination of niraparib, a poly (adp-ribose) polymerase (parp) inhibitor, and abiraterone acetate, a cyp17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved test for akeega. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 oncogenic variants, one recommended therapy is abiraterone acetate + niraparib + prednisone. therapy type: hormone therapy + targeted therapy + chemotherapy. therapy strategy: antiandrogen + parp inhibition + corticosteroid. indication: akeega is a combination of niraparib, a poly (adp-ribose) polymerase (parp) inhibitor, and abiraterone acetate, a cyp17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved test for akeega. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 pathogenic variants, one recommended therapy is abiraterone acetate + niraparib + prednisone. therapy type: hormone therapy + targeted therapy + chemotherapy. therapy strategy: antiandrogen + parp inhibition + corticosteroid. indication: akeega is a combination of niraparib, a poly (adp-ribose) polymerase (parp) inhibitor, and abiraterone acetate, a cyp17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved test for akeega. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has kras p.g12c, one recommended therapy is adagrasib. therapy type: targeted therapy. therapy strategy: ras inhibition. indication: krazati is an inhibitor of the ras gtpase family indicated for the treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior systemic therapy. this indication is approved under accelerated approval based on objective response rate (orr) and duration of response (dor). continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab emtansine. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: kadcyla is a her2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with her2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. patients should have either: received prior therapy for metastatic disease; or developed disease recurrence during or within six months of completing adjuvant therapy. select patients for therapy based on an fda-approved companion diagnostic for kadcyla. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf", "if a patient with early invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab emtansine. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: kadcyla is a her2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the adjuvant treatment of patients with her2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. select patients for therapy based on an fda-approved companion diagnostic for kadcyla. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr somatic variants, one recommended therapy is afatinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: gilotrif is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have non-resistant epidermal growth factor receptor (egfr) mutations as detected by an fda-approved test (1.1) limitations of use: safety and efficacy of gilotrif were not established in patients whose tumors have resistant egfr mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is alectinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: alecensa is a kinase inhibitor indicated for the adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) (tumors >= 4 cm or node positive) as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf", "if a patient with metastatic non-small cell lung cancer has v::alk, one recommended therapy is alectinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: alecensa is a kinase inhibitor indicated for the treatment of adult patients with alk-positive metastatic nsclc as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, pik3ca somatic variants, one recommended therapy is fulvestrant + alpelisib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: piqray is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3ca-mutated, advanced or metastatic breast cancer as detected by an fda-approved test following progression on or after an endocrine-based regimen. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, pik3ca somatic variants, one recommended therapy is fulvestrant + alpelisib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: piqray is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3ca-mutated, advanced or metastatic breast cancer as detected by an fda-approved test following progression on or after an endocrine-based regimen. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, pik3ca somatic variants, one recommended therapy is fulvestrant + alpelisib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: piqray is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3ca-mutated, advanced or metastatic breast cancer as detected by an fda-approved test following progression on or after an endocrine-based regimen. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has egfr exon 20 (insertion), one recommended therapy is amivantamab + pemetrexed + carboplatin. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: egfr inhibition + antifolate + platinum-based chemotherapy. indication: rybrevant is a bispecific egf receptor-directed and met receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 insertion mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has egfr exon 20 (insertion), one recommended therapy is amivantamab. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: rybrevant is a bispecific egf receptor-directed and met receptor-directed antibody indicated as a single agent for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 20 insertion mutations, as detected by an fda-approved test, whose disease has progressed on or after platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf", "if a patient with low-risk apl with pml-rara has pml::rara, one recommended therapy is arsenic trioxide. therapy type: targeted therapy. therapy strategy: pml::rara inhibition. indication: trisenox is an arsenical indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (apl) whose apl is characterized by the presence of the t(15;17) translocation or pml/rar-alpha gene expression. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf", "if a patient with apl with pml-rara has pml::rara, one recommended therapy is arsenic trioxide. therapy type: targeted therapy. therapy strategy: pml::rara inhibition. indication: trisenox is an arsenical indicated for induction of remission and consolidation in patients with apl who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterized by the presence of the t(15;17) translocation or pml/rar-alpha gene expression. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia has bcr::abl1, one recommended therapy is asciminib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: scemblix is a kinase inhibitor indicated for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia has abl1 p.t315i, bcr::abl1, one recommended therapy is asciminib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: scemblix is a kinase inhibitor indicated for the treatment of adult patients with ph+ cml in cp with the t315i mutation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf", "if a patient with non-small cell lung cancer has pd-l1 >= 1%, one recommended therapy is atezolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage ii to iiia nsclc whose tumors have pd-l1 expression on >= 1% of tumor cells, as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf", "if a patient with metastatic non-small cell lung cancer has pd-l1 >= 50%, one recommended therapy is atezolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated for the first-line treatment of adult patients with metastatic nsclc whose tumors have high pd-l1 expression (pd-l1 stained >= 50% of tumor cells [tc >= 50%] or pd-l1 stained tumor-infiltrating immune cells [ic] covering >= 10% of the tumor area [ic >= 10%] ), as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf", "if a patient with metastatic non-small cell lung cancer has pd-l1 >= 10% tiic, one recommended therapy is atezolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated for the first-line treatment of adult patients with metastatic nsclc whose tumors have high pd-l1 expression (pd-l1 stained >= 50% of tumor cells [tc >= 50%] or pd-l1 stained tumor-infiltrating immune cells [ic] covering >= 10% of the tumor area [ic >= 10%] ), as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf", "if a patient with metastatic non-squamous non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is bevacizumab + paclitaxel + atezolizumab + carboplatin. therapy type: targeted therapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: vegf inhibition + taxane-based chemotherapy + pd-1/pd-l1 inhibition + platinum-based chemotherapy. indication: tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous nsclc with no egfr or alk genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf", "if a patient with metastatic non-squamous non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is paclitaxel + atezolizumab + carboplatin. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: taxane-based chemotherapy + pd-1/pd-l1 inhibition + platinum-based chemotherapy. indication: tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous nsclc with no egfr or alk genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr somatic variants, one recommended therapy is atezolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated for the treatment of adult patients with metastatic nsclc who have disease progression during or following platinum-containing chemotherapy. patients with egfr or alk genomic tumor aberrations should have disease progression on fda-approved therapy for nsclc harboring these aberrations prior to receiving tecentriq. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf", "if a patient with metastatic non-small cell lung cancer has v::alk, one recommended therapy is atezolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated for the treatment of adult patients with metastatic nsclc who have disease progression during or following platinum-containing chemotherapy. patients with egfr or alk genomic tumor aberrations should have disease progression on fda-approved therapy for nsclc harboring these aberrations prior to receiving tecentriq. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600e, one recommended therapy is atezolizumab + vemurafenib + cobimetinib. therapy type: immunotherapy + targeted therapy + targeted therapy. therapy strategy: pd-1/pd-l1 inhibition + b-raf inhibition + mek inhibition. indication: tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with braf v600 mutation-positive unresectable or metastatic melanoma. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600k, one recommended therapy is atezolizumab + vemurafenib + cobimetinib. therapy type: immunotherapy + targeted therapy + targeted therapy. therapy strategy: pd-1/pd-l1 inhibition + b-raf inhibition + mek inhibition. indication: tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with braf v600 mutation-positive unresectable or metastatic melanoma. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf", "if a patient with unresectable or metastatic gastrointestinal stromal tumor has pdgfra p.d842v, one recommended therapy is avapritinib. therapy type: targeted therapy. therapy strategy: kit inhibition. indication: ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gist harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation, including pdgfra d842v mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600e, one recommended therapy is encorafenib + binimetinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600k, one recommended therapy is encorafenib + binimetinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf", "if a patient with metastatic non-small cell lung cancer has braf p.v600e, one recommended therapy is encorafenib + binimetinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with a braf v600e mutation, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf", "if a patient with early invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is letrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with b-cell precursor acute lymphoid leukemia has cd19 +, one recommended therapy is blinatumomab. therapy type: immunotherapy. therapy strategy: cd19 inhibition. indication: blincyto is a bispecific cd19-directed cd3 t-cell engager indicated for the treatment of adult and pediatric patients one month and older with cd19-positive b-cell precursor acute lymphoblastic leukemia (all) in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0.1%. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf", "if a patient with b-cell precursor acute lymphoid leukemia has cd19 +, one recommended therapy is blinatumomab. therapy type: immunotherapy. therapy strategy: cd19 inhibition. indication: blincyto is a bispecific cd19-directed cd3 t-cell engager indicated for the treatment of adult and pediatric patients one month and older with relapsed or refractory cd19-positive b-cell precursor acute lymphoblastic leukemia (all). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf", "if a patient with b-cell acute lymphoid leukemia has bcr::abl1, cd19 +, one recommended therapy is blinatumomab. therapy type: immunotherapy. therapy strategy: cd19 inhibition. indication: blincyto is a bispecific cd19-directed cd3 t-cell engager indicated for the treatment of adult and pediatric patients one month and older with cd19-positive philadelphia chromosome-negative b-cell precursor acute lymphoblastic leukemia (all) in the consolidation phase of multiphase chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf", "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia has bcr::abl1, one recommended therapy is bosutinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: bosulif is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with chronic phase ph+ chronic myelogenous leukemia (cml), newly-diagnosed or resistant or intolerant to prior therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia has bcr::abl1, one recommended therapy is bosutinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: bosulif is a kinase inhibitor indicated for the treatment of adult patients with accelerated, or blast phase ph+ cml with resistance or intolerance to prior therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf", "if a patient with systemic anaplastic large cell lymphoma has cd30 +, one recommended therapy is cyclophosphamide + doxorubicin + brentuximab vedotin + prednisone. therapy type: chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: alkylating chemotherapy + topoisomerase inhibition + target cd30 antigens + corticosteroid. indication: adcetris is a cd30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl) or other cd30-expressing peripheral t-cell lymphomas (ptcl), including angioimmunoblastic t-cell lymphoma and ptcl not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf", "if a patient with cutaneous anaplastic large cell lymphoma has cd30 +, one recommended therapy is brentuximab vedotin. therapy type: targeted therapy. therapy strategy: target cd30 antigens. indication: adcetris is a cd30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcalcl) or cd30-expressing mycosis fungoides (mf) who have received prior systemic therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf", "if a patient with metastatic non-small cell lung cancer has v::alk, one recommended therapy is brigatinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: alunbrig is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc) as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf", "if a patient with metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, one recommended therapy is capecitabine. therapy type: chemotherapy. therapy strategy: thymidylate synthase inhibition. indication: xeloda (capecitabine) is a nucleoside metabolic inhibitor indicated for treatment of adults with her2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s045s046s047s048s049s050s051lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has er positive, her2-negative, pik3ca somatic variants, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, pik3ca somatic variants, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, pik3ca somatic variants, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has er positive, her2-negative, akt1 somatic variants, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, akt1 somatic variants, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, akt1 somatic variants, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has akt1 amplification, er positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has akt1 amplification, pr positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has akt1 amplification, pr positive, er positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, er positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, pr positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, pr positive, er positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten frameshift variants, er positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten frameshift variants, pr positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten frameshift variants, pr positive, er positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, er positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, pr positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, pr positive, er positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten deletion, er positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten deletion, pr positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten deletion, pr positive, er positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf", "if a patient with metastatic non-small cell lung cancer has met exon 14 (splice site), one recommended therapy is capmatinib. therapy type: targeted therapy. therapy strategy: met inhibition. indication: tabrecta is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have a mutation that leads to mesenchymal-epithelial transition (met) exon 14 skipping as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf", "if a patient with metastatic non-small cell lung cancer has met exon 14 (deletion), one recommended therapy is capmatinib. therapy type: targeted therapy. therapy strategy: met inhibition. indication: tabrecta is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have a mutation that leads to mesenchymal-epithelial transition (met) exon 14 skipping as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, wild type ros1, one recommended therapy is cemiplimab + pemetrexed + carboplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: libtayo is a programmed death receptor-1 (pd-1) blocking antibody indicated in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) with no egfr, alk or ros1 aberrations and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, pd-l1 >= 50%, dmmr, one recommended therapy is cemiplimab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: libtayo is a programmed death receptor-1 (pd-1) blocking antibody indicated as single agent for the first-line treatment of adult patients with nsclc whose tumors have high pd-l1 expression [tumor proportion score (tps) >= 50%] as determined by an fda-approved test, with no egfr, alk or ros1 aberrations, and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf", "if a patient with metastatic non-small cell lung cancer has v::alk, one recommended therapy is ceritinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: zykadia is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf", "if a patient with metastatic colorectal adenocarcinoma has egfr positive, wild type kras, one recommended therapy is fluorouracil + irinotecan + cetuximab. therapy type: chemotherapy + chemotherapy + targeted therapy. therapy strategy: thymidylate synthase inhibition + topoisomerase i inhibition + egfr inhibition. indication: erbitux is an epidermal growth factor receptor (egfr) antagonist indicated for treatment of k-ras wild-type, egfr-expressing, metastatic colorectal cancer as determined by an fda-approved test in combination with folfiri for first-line treatment. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf", "if a patient with metastatic colorectal adenocarcinoma has egfr positive, wild type kras, one recommended therapy is irinotecan + cetuximab. therapy type: chemotherapy + targeted therapy. therapy strategy: topoisomerase i inhibition + egfr inhibition. indication: erbitux is an epidermal growth factor receptor (egfr) antagonist indicated for treatment of k-ras wild-type, egfr-expressing, metastatic colorectal cancer as determined by an fda-approved test in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf", "if a patient with metastatic colorectal adenocarcinoma has egfr positive, wild type kras, one recommended therapy is cetuximab. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: erbitux is an epidermal growth factor receptor (egfr) antagonist indicated for treatment of k-ras wild-type, egfr-expressing, metastatic colorectal cancer as determined by an fda-approved test as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf", "if a patient with metastatic colorectal adenocarcinoma has braf p.v600e, one recommended therapy is cetuximab + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + b-raf inhibition. indication: erbitux is an epidermal growth factor receptor (egfr) antagonist indicated for treatment of in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600e, one recommended therapy is vemurafenib + cobimetinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: cotellic is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, in combination with vemurafenib. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600k, one recommended therapy is vemurafenib + cobimetinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: cotellic is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, in combination with vemurafenib. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf", "if a patient with metastatic non-small cell lung cancer has v::alk, one recommended therapy is crizotinib. therapy type: targeted therapy. therapy strategy: alk inhibition + met inhibition + ros1 inhibition. indication: xalkori is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk) or ros1-positive as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf", "if a patient with metastatic non-small cell lung cancer has v::ros1, one recommended therapy is crizotinib. therapy type: targeted therapy. therapy strategy: alk inhibition + met inhibition + ros1 inhibition. indication: xalkori is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk) or ros1-positive as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf", "if a patient with anaplastic large cell lymphoma has v::alk, one recommended therapy is crizotinib. therapy type: targeted therapy. therapy strategy: alk inhibition + met inhibition + ros1 inhibition. indication: xalkori is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is alk-positive. limitations of use: the safety and efficacy of xalkori have not been established in older adults with relapsed or refractory, systemic alk-positive alcl. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf", "if a patient with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor has v::alk, one recommended therapy is crizotinib. therapy type: targeted therapy. therapy strategy: alk inhibition + met inhibition + ros1 inhibition. indication: xalkori is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (imt) that is alk-positive. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600e, one recommended therapy is dabrafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: tafinlar is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600e, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600k, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "if a patient with melanoma has braf p.v600e, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "if a patient with melanoma has braf p.v600k, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "if a patient with early invasive breast carcinoma has er positive, her2-negative, one recommended therapy is letrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with metastatic non-small cell lung cancer has braf p.v600e, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: tafinlar is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "if a patient with locally advanced or metastatic anaplastic thyroid cancer has braf p.v600e, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: tafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "if a patient with unresectable or metastatic any solid tumor has braf p.v600e, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: tafinlar is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. this indication is approved under accelerated approval based on overall response rate (orr) and duration of response (dor). continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "if a patient with low-grade glioma, nos has braf p.v600e, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: tafinlar is indicated, in combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is dacomitinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: vizimpro is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 19 deletion or exon 21 l858r substitution mutations as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr p.l858r, one recommended therapy is dacomitinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: vizimpro is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 19 deletion or exon 21 l858r substitution mutations as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is a kinase inhibitor indicated for the treatment of newly diagnosed adults with philadelphia chromosome-positive (ph+) chronic myeloid leukemia (cml) in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is a kinase inhibitor indicated for the treatment of newly diagnosed adults with philadelphia chromosome-positive (ph+) chronic myeloid leukemia (cml) in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf", "if a patient with chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myelogenous leukemia has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is a kinase inhibitor indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase ph+ cml with resistance or intolerance to prior therapy including imatinib. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf", "if a patient with chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myeloid leukemia, bcr-abl1+ has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is a kinase inhibitor indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase ph+ cml with resistance or intolerance to prior therapy including imatinib. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf", "if a patient with philadelphia chromosome-positive acute lymphoid leukemia has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is a kinase inhibitor indicated for the treatment of adults with philadelphia chromosome-positive acute lymphoblastic leukemia (ph+ all) with resistance or intolerance to prior therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with ph+ cml in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with ph+ cml in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf", "if a patient with philadelphia chromosome-positive acute lymphoid leukemia has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed ph+ all in combination with chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf", "if a patient with primary advanced or recurrent endometrial carcinoma has dmmr, one recommended therapy is dostarlimab + paclitaxel + carboplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: jemperli is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with carboplatin and paclitaxel, followed by jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dmmr), as determined by an fda-approved test, or microstallite instability-high (msi-h). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf", "if a patient with primary advanced or recurrent endometrial carcinoma has msi-h, one recommended therapy is dostarlimab + paclitaxel + carboplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: jemperli is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with carboplatin and paclitaxel, followed by jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dmmr), as determined by an fda-approved test, or microstallite instability-high (msi-h). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf", "if a patient with recurrent or advanced endometrial carcinoma has dmmr, one recommended therapy is dostarlimab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: jemperli is a programmed death receptor-1 (pd-1)-blocking antibody indicated as a single agent for the treatment of adult patients with dmmr recurrent or advanced endometrial cancer, as determined by an fda-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf", "if a patient with recurrent or advanced any solid tumor has dmmr, one recommended therapy is dostarlimab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: jemperli is a programmed death receptor-1 (pd-1)-blocking antibody indicated as a single agent for the treatment of adult patients with dmmr recurrent or advanced solid tumors, as determined by an fda-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf", "if a patient with metastatic non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + pemetrexed + carboplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf", "if a patient with metastatic non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + cisplatin + pemetrexed. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + platinum-based chemotherapy + antifolate. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf", "if a patient with metastatic non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + gemcitabine + carboplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + antimetabolite + platinum-based chemotherapy. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf", "if a patient with metastatic non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + cisplatin + gemcitabine. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + platinum-based chemotherapy + antimetabolite. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf", "if a patient with metastatic non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + nab-paclitaxel + carboplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf", "if a patient with primary advanced or recurrent endometrial carcinoma has dmmr, one recommended therapy is durvalumab + paclitaxel + carboplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with carboplatin and paclitaxel followed by imfinzi as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dmmr). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has esr1 oncogenic variants, er positive, her2-negative, one recommended therapy is elacestrant. therapy type: hormone therapy. therapy strategy: er signaling inhibition. indication: orserdu is an estrogen receptor antagonist indicated for treatment of postmenopausal women or adult men, with er-positive, her2-negative, esr1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s001lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh2 p.r140q, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh2 p.r140l, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh2 p.r140g, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh2 p.r140w, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh2 p.r172k, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh2 p.r172m, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh2 p.r172g, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh2 p.r172s, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh2 p.r172w, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600e, one recommended therapy is encorafenib + binimetinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda-approved test. braftovi is not indicated for treatment of patients with wild-type braf melanoma, wild-type braf crc, or wild-type braf nsclc. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600k, one recommended therapy is encorafenib + binimetinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda-approved test. braftovi is not indicated for treatment of patients with wild-type braf melanoma, wild-type braf crc, or wild-type braf nsclc. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf", "if a patient with metastatic colorectal adenocarcinoma has braf p.v600e, one recommended therapy is cetuximab + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + b-raf inhibition. indication: braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy. braftovi is not indicated for treatment of patients with wild-type braf melanoma, wild-type braf crc, or wild-type braf nsclc. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf", "if a patient with metastatic non-small cell lung cancer has braf p.v600e, one recommended therapy is encorafenib + binimetinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with a braf v600e mutation, as detected by an fda-approved test. braftovi is not indicated for treatment of patients with wild-type braf melanoma, wild-type braf crc, or wild-type braf nsclc. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf", "if a patient with metastatic non-small cell lung cancer has v::ros1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult patients with ros1-positive metastatic non-small cell lung cancer (nsclc) as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf", "if a patient with any solid tumor has v::ntrk1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf", "if a patient with any solid tumor has v::ntrk2, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf", "if a patient with any solid tumor has v::ntrk3, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf", "if a patient with locally advanced or metastatic bladder urothelial carcinoma has fgfr3 p.r248c, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (muc) with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. select patients for therapy based on an fda-approved companion diagnostic for balversa. balversa is not recommended for the treatment of patients who are eligible for and have not received prior pd-1 or pd-l1 inhibitor therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf", "if a patient with locally advanced or metastatic bladder urothelial carcinoma has fgfr3 p.s249c, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (muc) with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. select patients for therapy based on an fda-approved companion diagnostic for balversa. balversa is not recommended for the treatment of patients who are eligible for and have not received prior pd-1 or pd-l1 inhibitor therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf", "if a patient with locally advanced or metastatic bladder urothelial carcinoma has fgfr3 p.g370c, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (muc) with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. select patients for therapy based on an fda-approved companion diagnostic for balversa. balversa is not recommended for the treatment of patients who are eligible for and have not received prior pd-1 or pd-l1 inhibitor therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf", "if a patient with locally advanced or metastatic bladder urothelial carcinoma has fgfr3 p.y373c, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (muc) with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. select patients for therapy based on an fda-approved companion diagnostic for balversa. balversa is not recommended for the treatment of patients who are eligible for and have not received prior pd-1 or pd-l1 inhibitor therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf", "if a patient with locally advanced or metastatic bladder urothelial carcinoma has fgfr3::tacc3, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (muc) with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. select patients for therapy based on an fda-approved companion diagnostic for balversa. balversa is not recommended for the treatment of patients who are eligible for and have not received prior pd-1 or pd-l1 inhibitor therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is erlotinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tarceva is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. safety and efficacy of tarceva have not been established in patients with nsclc whose tumors have other egfr mutations. tarceva is not recommended for use in combination with platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr p.l858r, one recommended therapy is erlotinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tarceva is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. safety and efficacy of tarceva have not been established in patients with nsclc whose tumors have other egfr mutations. tarceva is not recommended for use in combination with platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf", "if a patient with invasive breast carcinoma has er positive, her2-negative, one recommended therapy is exemestane + everolimus. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + pi3k/akt/mtor inhibition. indication: afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, her2 negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is exemestane + everolimus. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + pi3k/akt/mtor inhibition. indication: afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, her2 negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf", "if a patient with invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is exemestane + everolimus. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + pi3k/akt/mtor inhibition. indication: afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, her2 negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf", "if a patient with invasive breast carcinoma has er positive, her2-negative, one recommended therapy is fulvestrant. therapy type: hormone therapy. therapy strategy: estrogen receptor inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is fulvestrant. therapy type: hormone therapy. therapy strategy: estrogen receptor inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is fulvestrant. therapy type: hormone therapy. therapy strategy: estrogen receptor inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with invasive breast carcinoma has er positive, one recommended therapy is fulvestrant. therapy type: hormone therapy. therapy strategy: estrogen receptor inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with invasive breast carcinoma has pr positive, one recommended therapy is fulvestrant. therapy type: hormone therapy. therapy strategy: estrogen receptor inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with invasive breast carcinoma has pr positive, er positive, one recommended therapy is fulvestrant. therapy type: hormone therapy. therapy strategy: estrogen receptor inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is fulvestrant + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is fulvestrant + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is fulvestrant + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is fulvestrant + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is fulvestrant + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is fulvestrant + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is fulvestrant + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is fulvestrant + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is fulvestrant + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf", "if a patient with unresectable, locally or metastatic intrahepatic cholangiocarcinoma has fgfr2::v, one recommended therapy is futibatinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: lytgobi is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (fgfr2) gene fusions or other rearrangements. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214801s002lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is gefitinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: iressa is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test. limitation of use: safety and efficacy of iressa have not been established in patients whose tumors have egfr mutations other than exon 19 deletions or exon 21 (l858r) substitution mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr p.l858r, one recommended therapy is gefitinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: iressa is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test. limitation of use: safety and efficacy of iressa have not been established in patients whose tumors have egfr mutations other than exon 19 deletions or exon 21 (l858r) substitution mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf", "if a patient with acute lymphoid leukemia has cd33 +, one recommended therapy is gemtuzumab ozogamicin. therapy type: immunotherapy. therapy strategy: cd33 inhibition. indication: mylotarg is a cd33-directed antibody and cytotoxic drug conjugate indicated for treatment of newly-diagnosed cd33-positive acute myeloid leukemia (aml) in adults and pediatric patients 1 month and older. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf", "if a patient with acute lymphoid leukemia has cd33 +, one recommended therapy is gemtuzumab ozogamicin. therapy type: immunotherapy. therapy strategy: cd33 inhibition. indication: mylotarg is a cd33-directed antibody and cytotoxic drug conjugate indicated for treatment of relapsed or refractory cd33-positive aml in adults and pediatric patients 2 years and older. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf", "if a patient with relapsed or refractory acute lymphoid leukemia has flt3-itd, one recommended therapy is gilteritinib. therapy type: targeted therapy. therapy strategy: flt3 inhibition. indication: xospata is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf", "if a patient with relapsed or refractory acute lymphoid leukemia has flt3 p.d835y, one recommended therapy is gilteritinib. therapy type: targeted therapy. therapy strategy: flt3 inhibition. indication: xospata is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf", "if a patient with relapsed or refractory acute lymphoid leukemia has flt3 p.d835a, one recommended therapy is gilteritinib. therapy type: targeted therapy. therapy strategy: flt3 inhibition. indication: xospata is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf", "if a patient with relapsed or refractory acute lymphoid leukemia has flt3 p.d835e, one recommended therapy is gilteritinib. therapy type: targeted therapy. therapy strategy: flt3 inhibition. indication: xospata is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf", "if a patient with relapsed or refractory acute lymphoid leukemia has flt3 p.d835h, one recommended therapy is gilteritinib. therapy type: targeted therapy. therapy strategy: flt3 inhibition. indication: xospata is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf", "if a patient with relapsed or refractory acute lymphoid leukemia has flt3 p.d835n, one recommended therapy is gilteritinib. therapy type: targeted therapy. therapy strategy: flt3 inhibition. indication: xospata is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf", "if a patient with relapsed or refractory acute lymphoid leukemia has flt3 p.d835s, one recommended therapy is gilteritinib. therapy type: targeted therapy. therapy strategy: flt3 inhibition. indication: xospata is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf", "if a patient with relapsed or refractory acute lymphoid leukemia has flt3 p.d835v, one recommended therapy is gilteritinib. therapy type: targeted therapy. therapy strategy: flt3 inhibition. indication: xospata is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in blast crisis (bc), accelerated phase (ap), or in chronic phase (cp) after failure of interferon-alpha therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in blast crisis (bc), accelerated phase (ap), or in chronic phase (cp) after failure of interferon-alpha therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "if a patient with philadelphia chromosome-positive acute lymphoid leukemia has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "if a patient with philadelphia chromosome-positive acute lymphoid leukemia has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) in combination with chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "if a patient with myelodysplastic syndromes has pdgfra rearrangements, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "if a patient with myelodysplastic syndromes has pdgfrb rearrangements, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "if a patient with aggressive systemic mastocytosis has kit p.d816v, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of adult patients with aggressive systemic mastocytosis (asm) without the d816v c-kit mutation or with c-kit mutational status unknown. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "if a patient with chronic eosinophilic leukemia, nos has fip1l1::pdgfra, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukemia (cel) who have the fip1l1-pdgfra fusion kinase (mutational analysis or fluorescence in situ hybridization [fish] demonstration of chic2 allele deletion) and for patients with hes and/or cel who are fip1l1-pdgfra fusion kinase negative or unknown. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "if a patient with unresectable and/or metastatic maligant gastrointestinal stromal tumor has cd117 +, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "if a patient with gastrointestinal stromal tumor has fip1l1::pdgfra, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the adjuvant treatment of adult patients following resection of kit (cd117) positive gist. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "if a patient with unresectable locally advanced or metastatic cholangiocarcinoma has fgfr2::v, one recommended therapy is infigratinib. therapy type: targeted therapy. therapy strategy: fgfr2 inhibition. indication: truseltiq is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as detected by an fda-approved test. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf", "if a patient with b-cell precursor acute lymphoid leukemia has cd22 +, one recommended therapy is inotuzumab ozogamicin. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: besponsa is a cd22-directed antibody and cytotoxic drug conjugate indicated for the treatment of relapsed or refractory cd22-positive b-cell precursor acute lymphoblastic leukemia (all) in adult and pediatric patients 1 year and older. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf", "if a patient with metastatic colorectal adenocarcinoma has msi-h, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: yervoy is a human cytotoxic t-lymphocyte antigen 4 (ctla-4)-blocking antibody indicated for treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) colorectal cancer in combination with nivolumab. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf", "if a patient with metastatic colorectal adenocarcinoma has dmmr, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: yervoy is a human cytotoxic t-lymphocyte antigen 4 (ctla-4)-blocking antibody indicated for treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) colorectal cancer in combination with nivolumab. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf", "if a patient with metastatic non-small cell lung cancer has wild type egfr, wild type alk, pd-l1 >= 1%, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: yervoy is a human cytotoxic t-lymphocyte antigen 4 (ctla-4)-blocking antibody indicated for treatment of adult patients with metastatic non-small cell lung cancer expressing pd-l1 (>=1%) as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations, as first-line treatment in combination with nivolumab. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf", "if a patient with metastatic or recurrent non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + ipilimumab + pemetrexed + carboplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition + antifolate + platinum-based chemotherapy. indication: yervoy is a human cytotoxic t-lymphocyte antigen 4 (ctla-4)-blocking antibody indicated for treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no egfr or alk genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf", "if a patient with metastatic or recurrent non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + cisplatin + ipilimumab + pemetrexed. therapy type: immunotherapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + platinum-based chemotherapy + ctla-4 inhibition + antifolate. indication: yervoy is a human cytotoxic t-lymphocyte antigen 4 (ctla-4)-blocking antibody indicated for treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no egfr or alk genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf", "if a patient with metastatic or recurrent non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + ipilimumab + paclitaxel + carboplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: yervoy is a human cytotoxic t-lymphocyte antigen 4 (ctla-4)-blocking antibody indicated for treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no egfr or alk genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132c, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132g, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132h, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132l, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132s, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132c, one recommended therapy is azacitidine + ivosidenib. therapy type: chemotherapy + targeted therapy. therapy strategy: hypomethylating agent chemotherapy + idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132g, one recommended therapy is azacitidine + ivosidenib. therapy type: chemotherapy + targeted therapy. therapy strategy: hypomethylating agent chemotherapy + idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132h, one recommended therapy is azacitidine + ivosidenib. therapy type: chemotherapy + targeted therapy. therapy strategy: hypomethylating agent chemotherapy + idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132l, one recommended therapy is azacitidine + ivosidenib. therapy type: chemotherapy + targeted therapy. therapy strategy: hypomethylating agent chemotherapy + idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132s, one recommended therapy is azacitidine + ivosidenib. therapy type: chemotherapy + targeted therapy. therapy strategy: hypomethylating agent chemotherapy + idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh1 p.r132c, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with relapsed or refractory aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh1 p.r132g, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with relapsed or refractory aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh1 p.r132h, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with relapsed or refractory aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh1 p.r132l, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with relapsed or refractory aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh1 p.r132s, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with relapsed or refractory aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with relapsed or refractory myelodysplastic syndromes has idh1 p.r132c, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with relapsed or refractory myelodysplastic syndromes has idh1 p.r132g, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with relapsed or refractory myelodysplastic syndromes has idh1 p.r132h, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with relapsed or refractory myelodysplastic syndromes has idh1 p.r132l, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with relapsed or refractory myelodysplastic syndromes has idh1 p.r132s, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with locally advanced or metastatic cholangiocarcinoma has idh1 p.r132c, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with locally advanced or metastatic cholangiocarcinoma has idh1 p.r132g, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with locally advanced or metastatic cholangiocarcinoma has idh1 p.r132h, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with locally advanced or metastatic cholangiocarcinoma has idh1 p.r132l, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with locally advanced or metastatic cholangiocarcinoma has idh1 p.r132s, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has her2-positive, one recommended therapy is capecitabine + lapatinib. therapy type: chemotherapy + targeted therapy. therapy strategy: thymidylate synthase inhibition + her2 inhibition. indication: tykerb is a kinase inhibitor indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (her2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. limitations of use: patients should have disease progression on trastuzumab prior to initiation of treatment with tykerb in combination with capecitabine. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, er positive, one recommended therapy is letrozole + lapatinib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + her2 inhibition. indication: tykerb is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, pr positive, one recommended therapy is letrozole + lapatinib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + her2 inhibition. indication: tykerb is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, pr positive, er positive, one recommended therapy is letrozole + lapatinib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + her2 inhibition. indication: tykerb is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf", "if a patient with any solid tumor has v::ntrk1, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf", "if a patient with any solid tumor has v::ntrk2, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf", "if a patient with any solid tumor has v::ntrk3, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf", "if a patient with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes has 5q deletion, one recommended therapy is lenalidomide. therapy type: chemotherapy. therapy strategy: angiogenesis inhibition. indication: revlimid is a thalidomide analogue indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021880s067lbl.pdf", "if a patient with metastatic non-small cell lung cancer has v::alk, one recommended therapy is lorlatinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: lorbrena is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is capecitabine + margetuximab. therapy type: chemotherapy + hormone therapy. therapy strategy: thymidylate synthase inhibition + her2 inhibition. indication: margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is margetuximab + eribulin. therapy type: hormone therapy + chemotherapy. therapy strategy: her2 inhibition + tubulin polymerization inhibition. indication: margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is margetuximab + gemcitabine. therapy type: hormone therapy + chemotherapy. therapy strategy: her2 inhibition + antimetabolite. indication: margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is vinorelbine + margetuximab. therapy type: chemotherapy + hormone therapy. therapy strategy: vinca alkaloid chemotherapy + her2 inhibition. indication: margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf", "if a patient with acute myeloid leukemia has flt3-itd, one recommended therapy is midostaurin + daunorubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + topoisomerase inhibition + dna polymerase inhibition. indication: rydapt is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 mutation- positive as detected by an fda-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. rydapt is not indicated as a single-agent induction therapy for the treatment of patients with aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf", "if a patient with acute myeloid leukemia has flt3 p.d835y, one recommended therapy is midostaurin + daunorubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + topoisomerase inhibition + dna polymerase inhibition. indication: rydapt is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 mutation- positive as detected by an fda-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. rydapt is not indicated as a single-agent induction therapy for the treatment of patients with aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf", "if a patient with acute myeloid leukemia has flt3 p.d835a, one recommended therapy is midostaurin + daunorubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + topoisomerase inhibition + dna polymerase inhibition. indication: rydapt is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 mutation- positive as detected by an fda-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. rydapt is not indicated as a single-agent induction therapy for the treatment of patients with aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf", "if a patient with acute myeloid leukemia has flt3 p.d835e, one recommended therapy is midostaurin + daunorubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + topoisomerase inhibition + dna polymerase inhibition. indication: rydapt is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 mutation- positive as detected by an fda-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. rydapt is not indicated as a single-agent induction therapy for the treatment of patients with aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf", "if a patient with acute myeloid leukemia has flt3 p.d835h, one recommended therapy is midostaurin + daunorubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + topoisomerase inhibition + dna polymerase inhibition. indication: rydapt is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 mutation- positive as detected by an fda-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. rydapt is not indicated as a single-agent induction therapy for the treatment of patients with aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf", "if a patient with acute myeloid leukemia has flt3 p.d835n, one recommended therapy is midostaurin + daunorubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + topoisomerase inhibition + dna polymerase inhibition. indication: rydapt is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 mutation- positive as detected by an fda-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. rydapt is not indicated as a single-agent induction therapy for the treatment of patients with aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf", "if a patient with acute myeloid leukemia has flt3 p.d835s, one recommended therapy is midostaurin + daunorubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + topoisomerase inhibition + dna polymerase inhibition. indication: rydapt is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 mutation- positive as detected by an fda-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. rydapt is not indicated as a single-agent induction therapy for the treatment of patients with aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf", "if a patient with acute myeloid leukemia has flt3 p.d835v, one recommended therapy is midostaurin + daunorubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + topoisomerase inhibition + dna polymerase inhibition. indication: rydapt is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 mutation- positive as detected by an fda-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. rydapt is not indicated as a single-agent induction therapy for the treatment of patients with aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf", "if a patient with acute myeloid leukemia has flt3 p.i836del, one recommended therapy is midostaurin + daunorubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + topoisomerase inhibition + dna polymerase inhibition. indication: rydapt is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 mutation- positive as detected by an fda-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. rydapt is not indicated as a single-agent induction therapy for the treatment of patients with aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf", "if a patient with acute myeloid leukemia has cdk12 oncogenic variants, one recommended therapy is midostaurin + daunorubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + topoisomerase inhibition + dna polymerase inhibition. indication: rydapt is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 mutation- positive as detected by an fda-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. rydapt is not indicated as a single-agent induction therapy for the treatment of patients with aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has egfr exon 20 (insertion), one recommended therapy is mobocertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: exkivity is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 insertion mutations, as detected by an fda-approved test, whose disease has progressed on or after platinum-based chemotherapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s003lbl.pdf", "if a patient with early-stage invasive breast carcinoma has her2-positive, one recommended therapy is neratinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: nerlynx is a kinase inhibitor indicated as a single agent, for the extended adjuvant treatment of adult patients with early-stage her2-positive breast cancer, to follow adjuvant trastuzumab based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has her2-positive, one recommended therapy is capecitabine + neratinib. therapy type: chemotherapy + targeted therapy. therapy strategy: thymidylate synthase inhibition + her2 inhibition. indication: nerlynx is a kinase inhibitor indicated in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia has bcr::abl1, one recommended therapy is nilotinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: tasigna is a kinase inhibitor indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ has bcr::abl1, one recommended therapy is nilotinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: tasigna is a kinase inhibitor indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf", "if a patient with chronic phase or accelerated phase ph+ chronic myelogenous leukemia has bcr::abl1, one recommended therapy is nilotinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: tasigna is a kinase inhibitor indicated for the treatment of adult patients with chronic phase (cp) and accelerated phase (ap) ph+ cml resistant to or intolerant to prior therapy that included imatinib. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf", "if a patient with chronic phase or accelerated phase ph+ chronic myeloid leukemia, bcr-abl1+ has bcr::abl1, one recommended therapy is nilotinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: tasigna is a kinase inhibitor indicated for the treatment of adult patients with chronic phase (cp) and accelerated phase (ap) ph+ cml resistant to or intolerant to prior therapy that included imatinib. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf", "if a patient with recurrent ovarian epithelial tumor has brca1 pathogenic variants, one recommended therapy is niraparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: zejula is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline brca-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for zejula. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf", "if a patient with recurrent ovarian epithelial tumor has brca2 pathogenic variants, one recommended therapy is niraparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: zejula is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline brca-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for zejula. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf", "if a patient with recurrent high-grade serous fallopian tube cancer has brca1 pathogenic variants, one recommended therapy is niraparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: zejula is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline brca-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for zejula. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf", "if a patient with recurrent high-grade serous fallopian tube cancer has brca2 pathogenic variants, one recommended therapy is niraparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: zejula is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline brca-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for zejula. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf", "if a patient with recurrent peritoneal serous carcinoma has brca1 pathogenic variants, one recommended therapy is niraparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: zejula is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline brca-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for zejula. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf", "if a patient with recurrent peritoneal serous carcinoma has brca2 pathogenic variants, one recommended therapy is niraparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: zejula is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline brca-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for zejula. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + paclitaxel + carboplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: opdivo is a programmed death receptor-1 (pd-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known egfr mutations or alk rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent opdivo as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "if a patient with non-small cell lung cancer has pd-l1 >= 1%, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult patients with metastatic non-small cell lung cancer expressing pd-l1 (>= 1%) as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations, as first-line treatment in combination with ipilimumab. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "if a patient with advanced ovarian epithelial tumor has brca1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced ovarian epithelial tumor has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced ovarian epithelial tumor has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced ovarian epithelial tumor has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced high-grade serous fallopian tube cancer has brca1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced high-grade serous fallopian tube cancer has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced high-grade serous fallopian tube cancer has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced high-grade serous fallopian tube cancer has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced peritoneal serous carcinoma has brca1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced peritoneal serous carcinoma has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced peritoneal serous carcinoma has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced peritoneal serous carcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced ovarian epithelial tumor has brca1 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced ovarian epithelial tumor has brca1 pathogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced ovarian epithelial tumor has brca2 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced ovarian epithelial tumor has brca2 pathogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced ovarian epithelial tumor has hrd, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced high-grade serous fallopian tube cancer has brca1 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced high-grade serous fallopian tube cancer has brca1 pathogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced high-grade serous fallopian tube cancer has brca2 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced high-grade serous fallopian tube cancer has brca2 pathogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced high-grade serous fallopian tube cancer has hrd, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced peritoneal serous carcinoma has brca1 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced peritoneal serous carcinoma has brca1 pathogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced peritoneal serous carcinoma has brca2 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced peritoneal serous carcinoma has brca2 pathogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with advanced peritoneal serous carcinoma has hrd, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed ovarian epithelial tumor has brca1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed ovarian epithelial tumor has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed ovarian epithelial tumor has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed ovarian epithelial tumor has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed high-grade serous fallopian tube cancer has brca1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed high-grade serous fallopian tube cancer has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed high-grade serous fallopian tube cancer has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed high-grade serous fallopian tube cancer has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed peritoneal serous carcinoma has brca1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed peritoneal serous carcinoma has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed peritoneal serous carcinoma has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed peritoneal serous carcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with high risk early invasive breast carcinoma has brca1 pathogenic variants, her2-negative, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with high risk early invasive breast carcinoma has brca2 pathogenic variants, her2-negative, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic invasive breast carcinoma has brca1 pathogenic variants, her2-negative, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious gbrcam, her2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. patients with hormone receptor (hr)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic invasive breast carcinoma has brca2 pathogenic variants, her2-negative, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious gbrcam, her2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. patients with hormone receptor (hr)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic pancreatic adenocarcinoma has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gbrcam metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic pancreatic adenocarcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gbrcam metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has atm pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has atm oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has bard1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has bard1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brip1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brip1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has cdk12 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has cdk12 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has chek1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has chek1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has chek2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has chek2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has fancl pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has fancl oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has palb2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has palb2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has rad51b pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has rad51b oncogenic variants, one recommended therapy is talazoparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has rad51c pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has rad51c oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has rad51d pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has rad51d oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has rad54l pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has rad54l oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 oncogenic variants, one recommended therapy is olaparib + prednisolone + abiraterone acetate. therapy type: targeted therapy + chemotherapy + hormone therapy. therapy strategy: parp inhibition + corticosteroid + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 pathogenic variants, one recommended therapy is olaparib + prednisolone + abiraterone acetate. therapy type: targeted therapy + chemotherapy + hormone therapy. therapy strategy: parp inhibition + corticosteroid + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 oncogenic variants, one recommended therapy is olaparib + prednisolone + abiraterone acetate. therapy type: targeted therapy + chemotherapy + hormone therapy. therapy strategy: parp inhibition + corticosteroid + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 pathogenic variants, one recommended therapy is olaparib + prednisolone + abiraterone acetate. therapy type: targeted therapy + chemotherapy + hormone therapy. therapy strategy: parp inhibition + corticosteroid + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 oncogenic variants, one recommended therapy is olaparib + abiraterone acetate + prednisone. therapy type: targeted therapy + hormone therapy + chemotherapy. therapy strategy: parp inhibition + antiandrogen + corticosteroid. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 pathogenic variants, one recommended therapy is olaparib + abiraterone acetate + prednisone. therapy type: targeted therapy + hormone therapy + chemotherapy. therapy strategy: parp inhibition + antiandrogen + corticosteroid. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 oncogenic variants, one recommended therapy is olaparib + abiraterone acetate + prednisone. therapy type: targeted therapy + hormone therapy + chemotherapy. therapy strategy: parp inhibition + antiandrogen + corticosteroid. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 pathogenic variants, one recommended therapy is olaparib + abiraterone acetate + prednisone. therapy type: targeted therapy + hormone therapy + chemotherapy. therapy strategy: parp inhibition + antiandrogen + corticosteroid. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh1 p.r132c, one recommended therapy is olutasidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: rezlidhia is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with a susceptible idh1 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh1 p.r132g, one recommended therapy is olutasidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: rezlidhia is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with a susceptible idh1 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh1 p.r132h, one recommended therapy is olutasidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: rezlidhia is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with a susceptible idh1 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh1 p.r132l, one recommended therapy is olutasidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: rezlidhia is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with a susceptible idh1 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf", "if a patient with relapsed or refractory acute myeloid leukemia has idh1 p.r132s, one recommended therapy is olutasidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: rezlidhia is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with a susceptible idh1 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf", "if a patient with non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso is a kinase inhibitor indicated for adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf", "if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso is a kinase inhibitor indicated for adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr p.l858r, one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso is a kinase inhibitor indicated for the first-line treatment of adult patients with metastatic nsclc whose tumors have egfr exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso is a kinase inhibitor indicated for the first-line treatment of adult patients with metastatic nsclc whose tumors have egfr exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has egfr p.l858r, one recommended therapy is cisplatin + osimertinib + pemetrexed. therapy type: chemotherapy + targeted therapy + chemotherapy. therapy strategy: platinum-based chemotherapy + egfr inhibition + antifolate. indication: tagrisso is a kinase inhibitor indicated in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic nsclc whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has egfr p.l858r, one recommended therapy is osimertinib + pemetrexed + carboplatin. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: egfr inhibition + antifolate + platinum-based chemotherapy. indication: tagrisso is a kinase inhibitor indicated in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic nsclc whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is osimertinib + pemetrexed + carboplatin. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: egfr inhibition + antifolate + platinum-based chemotherapy. indication: tagrisso is a kinase inhibitor indicated in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic nsclc whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is cisplatin + osimertinib + pemetrexed. therapy type: chemotherapy + targeted therapy + chemotherapy. therapy strategy: platinum-based chemotherapy + egfr inhibition + antifolate. indication: tagrisso is a kinase inhibitor indicated in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic nsclc whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr p.t790m, one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso is a kinase inhibitor indicated for the treatment of adult patients with metastatic egfr t790m mutation-positive nsclc, as detected by an fda-approved test, whose disease has progressed on or after egfr tki therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is letrozole + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: ibrance is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is letrozole + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: ibrance is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is letrozole + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: ibrance is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is fulvestrant + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: ibrance is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is fulvestrant + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: ibrance is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is fulvestrant + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: ibrance is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf", "if a patient with metastatic colorectal adenocarcinoma has wild type hras, wild type kras, one recommended therapy is panitumumab + oxaliplatin + fluorouracil. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: egfr inhibition + platinum-based chemotherapy + thymidylate synthase inhibition. indication: vectibix is an epidermal growth factor receptor (egfr) antagonist indicated for the treatment of wild-type ras (defined as wild-type in both kras and nras as determined by an fda-approved test for this use) metastatic colorectal cancer (mcrc) in combination with folfox for first-line treatment. limitation of use: vectibix is not indicated for the treatment of patients with ras-mutant mcrc or for whom ras mutation status is unknown. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf", "if a patient with metastatic colorectal adenocarcinoma has wild type hras, wild type kras, one recommended therapy is panitumumab. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: vectibix is an epidermal growth factor receptor (egfr) antagonist indicated for the treatment of wild-type ras (defined as wild-type in both kras and nras as determined by an fda-approved test for this use) metastatic colorectal cancer (mcrc) as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. limitation of use: vectibix is not indicated for the treatment of patients with ras-mutant mcrc or for whom ras mutation status is unknown. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf", "if a patient with metastatic non-squamous non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is pembrolizumab + pemetrexed + carboplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous nsclc, with no egfr or alk genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with metastatic non-squamous non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is pembrolizumab + cisplatin + pemetrexed. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + platinum-based chemotherapy + antifolate. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous nsclc, with no egfr or alk genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, pd-l1 >= 1%, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated as a single agent for the first-line treatment of patients with nsclc expressing pd-l1 [tumor proportion score (tps) >=1%] as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations, and is: stage iii where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with metastatic non-small cell lung cancer has pd-l1 >= 1%, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated as a single agent for the treatment of patients with metastatic nsclc whose tumors express pd-l1 (tps >=1%) as determined by an fda-approved test, with disease progression on or after platinum containing chemotherapy. patients with egfr or alk genomic tumor aberrations should have disease progression on fda-approved therapy for these aberrations prior to receiving keytruda. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with metastatic or unresectable, recurrent head and neck squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent hnscc whose tumors express pd-l1 [combined positive score (cps) >=1] as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with unresectable or metastatic any solid tumor has dmmr, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) solid tumors, as determined by an fda approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with unresectable or metastatic any solid tumor has msi-h, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) solid tumors, as determined by an fda approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with unresectable or metastatic colorectal adenocarcinoma has dmmr, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic msi-h or dmmr colorectal cancer (crc) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with unresectable or metastatic colorectal adenocarcinoma has msi-h, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic msi-h or dmmr colorectal cancer (crc) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab + trastuzumab + fluorouracil + cisplatin. therapy type: immunotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab + capecitabine + trastuzumab + oxaliplatin. therapy type: immunotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + thymidylate synthase inhibition + her2 inhibition + platinum-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-negative, one recommended therapy is pembrolizumab + fluorouracil + cisplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-negative gastric or gastroesophageal junction (gej) adenocarcinoma. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-negative, one recommended therapy is pembrolizumab + capecitabine + oxaliplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-negative gastric or gastroesophageal junction (gej) adenocarcinoma. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with locally advanced or metastatic adenocarcinoma of the gastroesophageal junction has pd-l1 (cps) >= 10, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (gej) (tumors with epicenter 1 to 5 centimeters above the gej) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express pd-l1 (cps >=10) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with locally advanced or metastatic esophageal adenocarcinoma has pd-l1 (cps) >= 10, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (gej) (tumors with epicenter 1 to 5 centimeters above the gej) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express pd-l1 (cps >=10) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with persistent, recurrent, or metastatic cervical adenocarcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab + cisplatin + paclitaxel. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + platinum-based chemotherapy + taxane-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with persistent, recurrent, or metastatic cervical squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab + cisplatin + paclitaxel. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + platinum-based chemotherapy + taxane-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with persistent, recurrent, or metastatic cervical adenocarcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab + bevacizumab + cisplatin + paclitaxel. therapy type: immunotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + vegf inhibition + platinum-based chemotherapy + taxane-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with persistent, recurrent, or metastatic cervical squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab + bevacizumab + cisplatin + paclitaxel. therapy type: immunotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + vegf inhibition + platinum-based chemotherapy + taxane-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with persistent, recurrent, or metastatic cervical adenocarcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab + paclitaxel + carboplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with persistent, recurrent, or metastatic cervical squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab + paclitaxel + carboplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with persistent, recurrent, or metastatic cervical adenocarcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab + bevacizumab + paclitaxel + carboplatin. therapy type: immunotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + vegf inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with persistent, recurrent, or metastatic cervical squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab + bevacizumab + paclitaxel + carboplatin. therapy type: immunotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + vegf inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with recurrent or metastatic cervical adenocarcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with recurrent or metastatic cervical squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with advanced endometrial carcinoma has msi-l, one recommended therapy is pembrolizumab + lenvatinib. therapy type: immunotherapy + targeted therapy. therapy strategy: pd-1/pd-l1 inhibition + vegfr inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pmmr) as determined by an fda-approved test or not msi-h, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with advanced endometrial carcinoma has pmmr, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated as a single agent, for the treatment of patients with advanced endometrial carcinoma that is msi-h or dmmr, as determined by an fda-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with advanced endometrial carcinoma has msi-h, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated as a single agent, for the treatment of patients with advanced endometrial carcinoma that is msi-h or dmmr, as determined by an fda-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with unresectable or metastatic any solid tumor has tmb-h (>= 10 mutations / mb), one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (tmb-h) [>=10 mutations/megabase (mut/mb)] solid tumors, as determined by an fda-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. the safety and effectiveness of keytruda in pediatric patients with tmb-h central nervous system cancers have not been established. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with high-risk early-stage triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is pembrolizumab + cyclophosphamide + doxorubicin + paclitaxel + carboplatin. therapy type: immunotherapy + chemotherapy + chemotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + alkylating chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage tnbc in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma has er negative, pr negative, pd-l1 (cps) >= 10, her2-negative, one recommended therapy is pembrolizumab + paclitaxel. therapy type: immunotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + taxane-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic tnbc whose tumors express pd-l1 (cps >=10) as determined by an fda approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma has er negative, pr negative, pd-l1 (cps) >= 10, her2-negative, one recommended therapy is pembrolizumab + gemcitabine + carboplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + antimetabolite + platinum-based chemotherapy. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic tnbc whose tumors express pd-l1 (cps >=10) as determined by an fda approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with unresectable locally advanced or metastatic cholangiocarcinoma has fgfr2::v, one recommended therapy is pemigatinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: pemazyre is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as detected by an fda-approved test. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf", "if a patient with unresectable locally advanced or metastatic cholangiocarcinoma has fgfr2 rearrangements, one recommended therapy is pemigatinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: pemazyre is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as detected by an fda-approved test. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf", "if a patient with relapsed or refractory myeloid/lymphoid neoplasms has fgfr1 rearrangements, one recommended therapy is pemigatinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: pemazyre is a kinase inhibitor indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (mlns) with fgfr1 rearrangement. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + pertuzumab + docetaxel. therapy type: targeted therapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + her2 inhibition + taxane-based chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and docetaxel for treatment of patients with her2-positive metastatic breast cancer (mbc) who have not received prior anti-her2 therapy or chemotherapy for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "if a patient with locally advanced, inflammatory, or early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + cyclophosphamide + doxorubicin + paclitaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + alkylating chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + her2 inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "if a patient with locally advanced, inflammatory, or early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + cyclophosphamide + pertuzumab + epirubicin + docetaxel. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + alkylating chemotherapy + her2 inhibition + topoisomerase inhibition + taxane-based chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + pertuzumab + docetaxel. therapy type: targeted therapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + her2 inhibition + taxane-based chemotherapy. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with docetaxel for treatment of patients with her2 positive metastatic breast cancer (mbc) who have not received prior anti-her2 therapy or chemotherapy for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "if a patient with early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + cyclophosphamide + paclitaxel + pertuzumab + epirubicin. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + alkylating chemotherapy + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "if a patient with early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + cyclophosphamide + doxorubicin + pertuzumab + docetaxel. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + alkylating chemotherapy + topoisomerase inhibition + her2 inhibition + taxane-based chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "if a patient with early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + cyclophosphamide + doxorubicin + paclitaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + alkylating chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + her2 inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "if a patient with early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + cyclophosphamide + pertuzumab + epirubicin + docetaxel. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + alkylating chemotherapy + her2 inhibition + topoisomerase inhibition + taxane-based chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "if a patient with early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + cyclophosphamide + paclitaxel + pertuzumab + epirubicin. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + alkylating chemotherapy + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "if a patient with early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + cyclophosphamide + doxorubicin + pertuzumab + docetaxel. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + alkylating chemotherapy + topoisomerase inhibition + her2 inhibition + taxane-based chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "if a patient with early invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + cyclophosphamide + pertuzumab + epirubicin + docetaxel. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + alkylating chemotherapy + her2 inhibition + topoisomerase inhibition + taxane-based chemotherapy. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "if a patient with early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + pertuzumab + docetaxel + carboplatin. therapy type: targeted therapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + her2 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "if a patient with locally advanced, inflammatory, or early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + cyclophosphamide + doxorubicin + paclitaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + alkylating chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + her2 inhibition. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "if a patient with locally advanced, inflammatory, or early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + cyclophosphamide + pertuzumab + epirubicin + docetaxel. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + alkylating chemotherapy + her2 inhibition + topoisomerase inhibition + taxane-based chemotherapy. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "if a patient with early invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + pertuzumab + docetaxel + carboplatin. therapy type: targeted therapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + her2 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "if a patient with early invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + cyclophosphamide + paclitaxel + pertuzumab + epirubicin. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + alkylating chemotherapy + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "if a patient with early invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + cyclophosphamide + doxorubicin + pertuzumab + docetaxel. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + alkylating chemotherapy + topoisomerase inhibition + her2 inhibition + taxane-based chemotherapy. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "if a patient with early invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + cyclophosphamide + doxorubicin + paclitaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + alkylating chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + her2 inhibition. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "if a patient with early invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + cyclophosphamide + pertuzumab + epirubicin + docetaxel. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + alkylating chemotherapy + her2 inhibition + topoisomerase inhibition + taxane-based chemotherapy. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "if a patient with early invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + cyclophosphamide + paclitaxel + pertuzumab + epirubicin. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + alkylating chemotherapy + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "if a patient with early invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + cyclophosphamide + doxorubicin + pertuzumab + docetaxel. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + alkylating chemotherapy + topoisomerase inhibition + her2 inhibition + taxane-based chemotherapy. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "if a patient with early invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + cyclophosphamide + doxorubicin + paclitaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + alkylating chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + her2 inhibition. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "if a patient with early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + cyclophosphamide + doxorubicin + paclitaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + alkylating chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + her2 inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "if a patient with early stage invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + cyclophosphamide + pertuzumab + epirubicin + docetaxel. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + alkylating chemotherapy + her2 inhibition + topoisomerase inhibition + taxane-based chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, one recommended therapy is ponatinib + vincristine + methotrexate + prednisone + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + chemotherapy. therapy strategy: bcr-abl inhibition + vinca alkaloid chemotherapy + antifolate + corticosteroid + dna polymerase inhibition. indication: iclusig is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed ph+ all, in combination with chemotherapy. this indication is approved under accelerated approval based on minimal residual disease (mrd)-negative complete remission (cr) at the end of induction. continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf", "if a patient with acute lymphoid leukemia has abl1 p.t315i, bcr::abl1, one recommended therapy is ponatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: iclusig is a kinase inhibitor indicated for the treatment of adult patients with as monotherapy in ph+ all for whom no other kinase inhibitors are indicated or t315i-positive ph+ all. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf", "if a patient with chronic myelogenous leukemia has abl1 p.t315i, one recommended therapy is ponatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: iclusig is a kinase inhibitor indicated for the treatment of adult patients with t315i-positive cml (chronic phase, accelerated phase, or blast phase). limitations of use: iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed cp-cml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf", "if a patient with non-small cell lung cancer has v::ret, one recommended therapy is pralsetinib. therapy type: targeted therapy. therapy strategy: ret inhibition. indication: gavreto is a kinase inhibitor indicated for treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer as detected by an fda approved test (nsclc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf", "if a patient with advanced or metastatic papillary thyroid cancer has v::ret, one recommended therapy is pralsetinib. therapy type: targeted therapy. therapy strategy: ret inhibition. indication: gavreto is a kinase inhibitor indicated for treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is erlotinib + ramucirumab. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + vegf/vegfr inhibition. indication: cyramza is a human vascular endothelial growth factor receptor 2 (vegfr2) antagonist indicated in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf", "if a patient with metastatic non-small cell lung cancer has egfr p.l858r, one recommended therapy is erlotinib + ramucirumab. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + vegf/vegfr inhibition. indication: cyramza is a human vascular endothelial growth factor receptor 2 (vegfr2) antagonist indicated in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has v::ros1, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf", "if a patient with any solid tumor has v::ntrk1, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf", "if a patient with any solid tumor has v::ntrk2, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf", "if a patient with any solid tumor has v::ntrk3, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is anastrozole + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is anastrozole + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is anastrozole + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is letrozole + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is letrozole + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is letrozole + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is fulvestrant + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is fulvestrant + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is fulvestrant + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with b-cell non-hodgkin lymphoma has cd20 +, one recommended therapy is rituximab. therapy type: immunotherapy. therapy strategy: cd20 inhibition. indication: rituxan is a cd20-directed cytolytic antibody indicated for the treatment of adult patients with relapsed or refractory, low grade or follicular, cd20-positive b- cell nhl as a single agent. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf", "if a patient with b-cell non-hodgkin lymphoma has cd20 +, one recommended therapy is vincristine + rituximab + prednisolone + cyclophosphamide. therapy type: chemotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: vinca alkaloid chemotherapy + cd20 inhibition + corticosteroid + alkylating chemotherapy. indication: rituxan is a cd20-directed cytolytic antibody indicated for the treatment of adult patients with previously untreated follicular, cd20-positive, b-cell non-hodgkin's lymphoma (nhl) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf", "if a patient with b-cell non-hodgkin lymphoma has cd20 +, one recommended therapy is vincristine + rituximab + prednisolone + cyclophosphamide + doxorubicin. therapy type: chemotherapy + immunotherapy + chemotherapy + chemotherapy + chemotherapy. therapy strategy: vinca alkaloid chemotherapy + cd20 inhibition + corticosteroid + alkylating chemotherapy + topoisomerase inhibition. indication: rituxan is a cd20-directed cytolytic antibody indicated for the treatment of adult patients with previously untreated follicular, cd20-positive, b-cell non-hodgkin's lymphoma (nhl) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf", "if a patient with b-cell non-hodgkin lymphoma has cd20 +, one recommended therapy is rituximab + mitoxantrone + fludarabine + cyclophosphamide. therapy type: immunotherapy + chemotherapy + chemotherapy + chemotherapy. therapy strategy: cd20 inhibition + topoisomerase inhibition + antimetabolite + alkylating chemotherapy. indication: rituxan is a cd20-directed cytolytic antibody indicated for the treatment of adult patients with previously untreated follicular, cd20-positive, b-cell non-hodgkin's lymphoma (nhl) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf", "if a patient with non-hodgkin lymphoma has cd20 +, one recommended therapy is vincristine + rituximab + cyclophosphamide + doxorubicin + prednisone. therapy type: chemotherapy + immunotherapy + chemotherapy + chemotherapy + chemotherapy. therapy strategy: vinca alkaloid chemotherapy + cd20 inhibition + alkylating chemotherapy + topoisomerase inhibition + corticosteroid. indication: rituxan is a cd20-directed cytolytic antibody indicated for the treatment of adult patients with non-hodgkin's lymphoma (nhl) non-progressing (including stable disease), low-grade, cd20 positive, b-cell nhl as a single agent after first-line cyclophosphamide, vincristine, and prednisone (cvp) chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf", "if a patient with diffuse large b-cell non-hodgkin lymphoma has cd20 +, one recommended therapy is vincristine + rituximab + cyclophosphamide + doxorubicin + prednisone. therapy type: chemotherapy + immunotherapy + chemotherapy + chemotherapy + chemotherapy. therapy strategy: vinca alkaloid chemotherapy + cd20 inhibition + alkylating chemotherapy + topoisomerase inhibition + corticosteroid. indication: rituxan is a cd20-directed cytolytic antibody indicated for the treatment of adult patients with non-hodgkin's lymphoma (nhl) previously untreated diffuse large b-cell, cd20-positive nhl in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (chop) or other anthracycline-based chemotherapy regimens. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf", "if a patient with previously untreated, advanced stage, cd20-positive diffuse large b-cell lymphoma has cd20 +, one recommended therapy is vincristine + rituximab + cyclophosphamide + doxorubicin + prednisone. therapy type: chemotherapy + immunotherapy + chemotherapy + chemotherapy + chemotherapy. therapy strategy: vinca alkaloid chemotherapy + cd20 inhibition + alkylating chemotherapy + topoisomerase inhibition + corticosteroid. indication: rituxan is a cd20-directed cytolytic antibody indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, cd20-positive, diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl), burkitt-like lymphoma (bll) or mature b-cell acute leukemia (b-al) in combination with chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf", "if a patient with previously untreated, advanced stage, cd20-positive burkitt lymphoma has cd20 +, one recommended therapy is vincristine + rituximab + cyclophosphamide + doxorubicin + prednisone. therapy type: chemotherapy + immunotherapy + chemotherapy + chemotherapy + chemotherapy. therapy strategy: vinca alkaloid chemotherapy + cd20 inhibition + alkylating chemotherapy + topoisomerase inhibition + corticosteroid. indication: rituxan is a cd20-directed cytolytic antibody indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, cd20-positive, diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl), burkitt-like lymphoma (bll) or mature b-cell acute leukemia (b-al) in combination with chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf", "if a patient with previously untreated, advanced stage, cd20-positive mature b-cell neoplasms has cd20 +, one recommended therapy is vincristine + rituximab + cyclophosphamide + doxorubicin + prednisone. therapy type: chemotherapy + immunotherapy + chemotherapy + chemotherapy + chemotherapy. therapy strategy: vinca alkaloid chemotherapy + cd20 inhibition + alkylating chemotherapy + topoisomerase inhibition + corticosteroid. indication: rituxan is a cd20-directed cytolytic antibody indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, cd20-positive, diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl), burkitt-like lymphoma (bll) or mature b-cell acute leukemia (b-al) in combination with chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf", "if a patient with chronic lymphocytic leukemia has cd20 +, one recommended therapy is rituximab + fludarabine + cyclophosphamide. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: cd20 inhibition + antimetabolite + alkylating chemotherapy. indication: rituxan is a cd20-directed cytolytic antibody indicated for the treatment of adult patients with previously untreated and previously treated cd20-positive chronic lymphocytic leukemia (cll). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf", "if a patient with ovarian epithelial tumor has brca1 oncogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with ovarian epithelial tumor has brca1 pathogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with ovarian epithelial tumor has brca2 oncogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with ovarian epithelial tumor has brca2 pathogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with high-grade serous fallopian tube cancer has brca1 oncogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with high-grade serous fallopian tube cancer has brca1 pathogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with high-grade serous fallopian tube cancer has brca2 oncogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with high-grade serous fallopian tube cancer has brca2 pathogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with peritoneal serous carcinoma has brca1 oncogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with peritoneal serous carcinoma has brca1 pathogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with peritoneal serous carcinoma has brca2 oncogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with peritoneal serous carcinoma has brca2 pathogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 oncogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with a deleterious brca mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor-directed therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 pathogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with a deleterious brca mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor-directed therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 oncogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with a deleterious brca mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor-directed therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 pathogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with a deleterious brca mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor-directed therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf", "if a patient with unresectable locally advanced or metastatic triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is sacituzumab govitecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition. indication: trodelvy is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, at least one of them for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has er positive, her2-negative, one recommended therapy is sacituzumab govitecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition. indication: trodelvy is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is sacituzumab govitecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition. indication: trodelvy is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is sacituzumab govitecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition. indication: trodelvy is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has v::ret, one recommended therapy is selpercatinib. therapy type: targeted therapy. therapy strategy: ret inhibition. indication: retevmo is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with a rearranged during transfection (ret) gene fusion, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf", "if a patient with advanced or metastatic medullary thyroid cancer has ret oncogenic variants, one recommended therapy is selpercatinib. therapy type: targeted therapy. therapy strategy: ret inhibition. indication: retevmo is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (mtc) with a ret mutation, as detected by an fda-approved test, who require systemic therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf", "if a patient with advanced or metastatic anaplastic thyroid cancer has v::ret, one recommended therapy is selpercatinib. therapy type: targeted therapy. therapy strategy: ret inhibition. indication: retevmo is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a ret gene fusion, as detected by an fda-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf", "if a patient with locally advanced or metastatic any solid tumor has v::ret, one recommended therapy is selpercatinib. therapy type: targeted therapy. therapy strategy: ret inhibition. indication: retevmo is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a ret gene fusion, as detected by an fda-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has kras p.g12c, one recommended therapy is sotorasib. therapy type: targeted therapy. therapy strategy: ras inhibition. indication: lumakras is an inhibitor of the ras gtpase family indicated for the treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior systemic therapy. this indication is approved under accelerated approval based on overall response rate (orr) and duration of response (dor). continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s004lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has brca1 pathogenic variants, her2-negative, one recommended therapy is talazoparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline brca-mutated (gbrcam) her2-negative locally advanced or metastatic breast cancer. select patients for therapy based on an fda-approved companion diagnostic for talzenna. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has brca2 pathogenic variants, her2-negative, one recommended therapy is talazoparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline brca-mutated (gbrcam) her2-negative locally advanced or metastatic breast cancer. select patients for therapy based on an fda-approved companion diagnostic for talzenna. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with non-small cell lung cancer has met exon 14 (splice site), one recommended therapy is tepotinib. therapy type: targeted therapy. therapy strategy: met inhibition. indication: tepmetko is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) harboring mesenchymal-epithelial transition (met) exon 14 skipping alterations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf", "if a patient with non-small cell lung cancer has met exon 14 (deletion), one recommended therapy is tepotinib. therapy type: targeted therapy. therapy strategy: met inhibition. indication: tepmetko is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) harboring mesenchymal-epithelial transition (met) exon 14 skipping alterations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600e, one recommended therapy is trametinib. therapy type: targeted therapy. therapy strategy: mek inhibition. indication: mekinist is a kinase inhibitor indicated as a single agent for the treatment of braf-inhibitor treatment-naive patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600k, one recommended therapy is trametinib. therapy type: targeted therapy. therapy strategy: mek inhibition. indication: mekinist is a kinase inhibitor indicated as a single agent for the treatment of braf-inhibitor treatment-naive patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600e, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: mekinist is indicated, in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600k, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: mekinist is indicated, in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "if a patient with metastatic non-small cell lung cancer has braf p.v600e, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "if a patient with locally advanced or metastatic anaplastic thyroid cancer has braf p.v600e, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "if a patient with unresectable or metastatic any solid tumor has braf p.v600e, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: mekinist is indicated, in combination with dabrafenib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). limitations of use: mekinist is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to braf inhibition. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "if a patient with low-grade glioma, nos has braf p.v600e, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: mekinist is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is a her2/neu receptor antagonist indicated for the treatment of her2 -overexpressing breast cancer. select patients for therapy based on an fda-approved companion diagnostic for herceptin. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf", "if a patient with metastatic gastrointestinal stromal tumor has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is a her2/neu receptor antagonist indicated for the treatment of her2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. select patients for therapy based on an fda-approved companion diagnostic for herceptin. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf", "if a patient with unresectable or metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic her2-positive (ihc 3+ or ish positive) breast cancer who have received a prior anti-her2-based regimen either (i) in the metastatic setting, or (ii) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf", "if a patient with unresectable or metastatic invasive breast carcinoma has her2-low, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic her2-low (ihc 1+ or ihc 2+/ish-) breast cancer, as determined by an fda-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf", "if a patient with unresectable or metastatic non-small cell lung cancer has erbb2 oncogenic variants, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (nsclc) whose tumors have activating her2 (erbb2) mutations, as detected by an fda-approved test, and who have received a prior systemic therapy. these indications are approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf", "if a patient with locally advanced or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic her2-positive (ihc 3+ or ihc 2+/ish positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf", "if a patient with unresectable or metastatic any solid tumor has her2-positive, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic her2-positive (ihc 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. these indications are approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf", "if a patient with unresectable or metastatic invasive breast carcinoma has her2-positive, one recommended therapy is capecitabine + trastuzumab + tucatinib. therapy type: chemotherapy + targeted therapy + targeted therapy. therapy strategy: thymidylate synthase inhibition + her2 inhibition + her2 inhibition. indication: tukysa is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic her2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-her2-based regimens in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf", "if a patient with unresectable or metastatic melanoma has braf p.v600e, one recommended therapy is vemurafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: zelboraf is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf", "if a patient with non-langerhans cell histiocytosis/erdheim-chester disease has braf p.v600e, one recommended therapy is vemurafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf", "if a patient with non-langerhans cell histiocytosis/erdheim-chester disease has braf p.v600k, one recommended therapy is vemurafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf", "if a patient with follicular lymphoma has ezh2 p.y646n, one recommended therapy is tazemetostat. therapy type: targeted therapy. therapy strategy: ezh2 inhibition. indication: tazverik is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an ezh2 mutation as detected by an fda-approved test and who have received at least 2 prior systemic therapies. these indications are approved under accelerated approval based on overall response rate and duration of response. continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf", "if a patient with follicular lymphoma has ezh2 p.y646f, one recommended therapy is tazemetostat. therapy type: targeted therapy. therapy strategy: ezh2 inhibition. indication: tazverik is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an ezh2 mutation as detected by an fda-approved test and who have received at least 2 prior systemic therapies. these indications are approved under accelerated approval based on overall response rate and duration of response. continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf", "if a patient with follicular lymphoma has ezh2 p.y646h, one recommended therapy is tazemetostat. therapy type: targeted therapy. therapy strategy: ezh2 inhibition. indication: tazverik is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an ezh2 mutation as detected by an fda-approved test and who have received at least 2 prior systemic therapies. these indications are approved under accelerated approval based on overall response rate and duration of response. continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf", "if a patient with follicular lymphoma has ezh2 p.y646s, one recommended therapy is tazemetostat. therapy type: targeted therapy. therapy strategy: ezh2 inhibition. indication: tazverik is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an ezh2 mutation as detected by an fda-approved test and who have received at least 2 prior systemic therapies. these indications are approved under accelerated approval based on overall response rate and duration of response. continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf", "if a patient with follicular lymphoma has ezh2 p.y646c, one recommended therapy is tazemetostat. therapy type: targeted therapy. therapy strategy: ezh2 inhibition. indication: tazverik is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an ezh2 mutation as detected by an fda-approved test and who have received at least 2 prior systemic therapies. these indications are approved under accelerated approval based on overall response rate and duration of response. continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf", "if a patient with follicular lymphoma has ezh2 p.a862g, one recommended therapy is tazemetostat. therapy type: targeted therapy. therapy strategy: ezh2 inhibition. indication: tazverik is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an ezh2 mutation as detected by an fda-approved test and who have received at least 2 prior systemic therapies. these indications are approved under accelerated approval based on overall response rate and duration of response. continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf", "if a patient with follicular lymphoma has ezh2 p.a692v, one recommended therapy is tazemetostat. therapy type: targeted therapy. therapy strategy: ezh2 inhibition. indication: tazverik is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an ezh2 mutation as detected by an fda-approved test and who have received at least 2 prior systemic therapies. these indications are approved under accelerated approval based on overall response rate and duration of response. continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has atm pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has atm oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has atr oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has cdk12 oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has atr pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has fanca oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has chek2 pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has chek2 oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has fanca pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has mlh1 oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has palb2 pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has palb2 oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has mlh1 pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has mre11 oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has rad51c pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has rad51c oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has mre11 pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has nbn oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has nbn pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with renal angiomyolipoma has tsc1 oncogenic variants, one recommended therapy is everolimus. therapy type: targeted therapy. therapy strategy: pi3k/akt/mtor inhibition. indication: afinitor is a kinase inhibitor indicated for the treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (tsc), not requiring immediate surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf", "if a patient with renal angiomyolipoma has tsc2 oncogenic variants, one recommended therapy is everolimus. therapy type: targeted therapy. therapy strategy: pi3k/akt/mtor inhibition. indication: afinitor is a kinase inhibitor indicated for the treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (tsc), not requiring immediate surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf", "if a patient with anaplastic thyroid cancer has tsc1 oncogenic variants, one recommended therapy is everolimus. therapy type: targeted therapy. therapy strategy: pi3k/akt/mtor inhibition. indication: afinitor and afinitor disperz are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with tsc who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf", "if a patient with anaplastic thyroid cancer has tsc2 oncogenic variants, one recommended therapy is everolimus. therapy type: targeted therapy. therapy strategy: pi3k/akt/mtor inhibition. indication: afinitor and afinitor disperz are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with tsc who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has cdk12 pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf", "if a patient with non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso is a kinase inhibitor indicated for the treatment of adult patients with locally advanced, unresectable (stage iii) nsclc whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have egfr exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf", "if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso is a kinase inhibitor indicated for the treatment of adult patients with locally advanced, unresectable (stage iii) nsclc whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have egfr exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is lazertinib + amivantamab. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + egfr inhibition. indication: rybrevant is a bispecific egf receptor-directed and met receptor-directed antibody indicated in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 19 deletions or exon 21 l858r substitution mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf", "if a patient with locally advanced or metastatic non-small cell lung cancer has egfr p.l858r, one recommended therapy is lazertinib + amivantamab. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + egfr inhibition. indication: rybrevant is a bispecific egf receptor-directed and met receptor-directed antibody indicated in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 19 deletions or exon 21 l858r substitution mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf", "if a patient with non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is lazertinib + amivantamab. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + egfr inhibition. indication: lazcluze is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r substitution mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf", "if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is lazertinib + amivantamab. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + egfr inhibition. indication: lazcluze is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r substitution mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf", "if a patient with non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is amivantamab + pemetrexed + carboplatin. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: egfr inhibition + antifolate + platinum-based chemotherapy. indication: rybrevant is a bispecific egf receptor-directed and met receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 19 deletions or exon 21 l858r substitution mutations, whose disease has progressed on or after treatment with an egfr tyrosine kinase inhibitor. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf", "if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is amivantamab + pemetrexed + carboplatin. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: egfr inhibition + antifolate + platinum-based chemotherapy. indication: rybrevant is a bispecific egf receptor-directed and met receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 19 deletions or exon 21 l858r substitution mutations, whose disease has progressed on or after treatment with an egfr tyrosine kinase inhibitor. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf", "if a patient with ovarian epithelial tumor has folr1 positive, one recommended therapy is mirvetuximab soravtansine. therapy type: chemotherapy. therapy strategy: folate receptor-alpha inhibition. indication: elahere is a folate receptor alpha (fr\u03b1)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with fr-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf", "if a patient with high-grade serous fallopian tube cancer has folr1 positive, one recommended therapy is mirvetuximab soravtansine. therapy type: chemotherapy. therapy strategy: folate receptor-alpha inhibition. indication: elahere is a folate receptor alpha (fr\u03b1)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with fr-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf", "if a patient with peritoneal serous carcinoma has folr1 positive, one recommended therapy is mirvetuximab soravtansine. therapy type: chemotherapy. therapy strategy: folate receptor-alpha inhibition. indication: elahere is a folate receptor alpha (fr\u03b1)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with fr-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf", "if a patient with low-grade glioma, nos has braf rearrangements, one recommended therapy is tovorafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: ojemda is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (lgg) harboring a braf fusion or rearrangement, or braf v600 mutation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf", "if a patient with low-grade glioma, nos has v::braf, one recommended therapy is tovorafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: ojemda is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (lgg) harboring a braf fusion or rearrangement, or braf v600 mutation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf", "if a patient with low-grade glioma, nos has braf p.v600e, one recommended therapy is tovorafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: ojemda is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (lgg) harboring a braf fusion or rearrangement, or braf v600 mutation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf", "if a patient with low-grade glioma, nos has braf p.v600k, one recommended therapy is tovorafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: ojemda is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (lgg) harboring a braf fusion or rearrangement, or braf v600 mutation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is durvalumab + paclitaxel + carboplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by imfinzi continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (nsclc) and no known epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) rearrangements. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is durvalumab + cisplatin + gemcitabine. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + platinum-based chemotherapy + antimetabolite. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by imfinzi continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (nsclc) and no known epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) rearrangements. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is durvalumab + cisplatin + pemetrexed. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + platinum-based chemotherapy + antifolate. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by imfinzi continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (nsclc) and no known epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) rearrangements. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is durvalumab + pemetrexed + carboplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by imfinzi continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (nsclc) and no known epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) rearrangements. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf", "if a patient with colorectal adenocarcinoma has kras p.g12c, one recommended therapy is cetuximab + adagrasib. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + ras inhibition. indication: krazati is an inhibitor of the ras gtpase family indicated in combination with cetuximab for the treatment of adult patients with kras g12c-mutated locally advanced or metastatic crc, as determined by an fda-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. these indications are approved under accelerated approval based on objective response rate (orr) and duration of response (dor). continued approval for these indications may be contingent upon verification and description of a clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf", "if a patient with astrocytoma has idh1 p.r132c, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with astrocytoma has idh1 p.r132g, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with astrocytoma has idh1 p.r132h, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with astrocytoma has idh1 p.r132l, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with astrocytoma has idh1 p.r132s, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with astrocytoma has idh2 p.r172k, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with astrocytoma has idh2 p.r172m, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with astrocytoma has idh2 p.r172g, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with astrocytoma has idh2 p.r172s, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with astrocytoma has idh2 p.r172w, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with oligodendroglioma has idh1 p.r132c, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with oligodendroglioma has idh1 p.r132g, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with oligodendroglioma has idh1 p.r132h, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with oligodendroglioma has idh1 p.r132l, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with oligodendroglioma has idh1 p.r132s, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with oligodendroglioma has idh2 p.r172k, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with oligodendroglioma has idh2 p.r172m, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with oligodendroglioma has idh2 p.r172g, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with oligodendroglioma has idh2 p.r172s, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with oligodendroglioma has idh2 p.r172w, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf", "if a patient with early invasive breast carcinoma has er positive, her2-negative, one recommended therapy is anastrozole + goserelin + ribociclib. therapy type: hormone therapy + hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + gonadotropin-releasing hormone (gnrh) agonist + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative stage ii and iii early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with early invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is anastrozole + goserelin + ribociclib. therapy type: hormone therapy + hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + gonadotropin-releasing hormone (gnrh) agonist + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative stage ii and iii early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with early invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is anastrozole + goserelin + ribociclib. therapy type: hormone therapy + hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + gonadotropin-releasing hormone (gnrh) agonist + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative stage ii and iii early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with early invasive breast carcinoma has er positive, her2-negative, one recommended therapy is letrozole + goserelin + ribociclib. therapy type: hormone therapy + hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + gonadotropin-releasing hormone (gnrh) agonist + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative stage ii and iii early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with early invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is letrozole + goserelin + ribociclib. therapy type: hormone therapy + hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + gonadotropin-releasing hormone (gnrh) agonist + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative stage ii and iii early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with early invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is letrozole + goserelin + ribociclib. therapy type: hormone therapy + hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + gonadotropin-releasing hormone (gnrh) agonist + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative stage ii and iii early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + cisplatin + pemetrexed. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + platinum-based chemotherapy + antifolate. indication: opdivo is a programmed death receptor-1 (pd-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known egfr mutations or alk rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent opdivo as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + cisplatin + gemcitabine. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + platinum-based chemotherapy + antimetabolite. indication: opdivo is a programmed death receptor-1 (pd-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known egfr mutations or alk rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent opdivo as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + ipilimumab + pemetrexed + carboplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition + antifolate + platinum-based chemotherapy. indication: opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no egfr or alk genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + cisplatin + ipilimumab + pemetrexed. therapy type: immunotherapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + platinum-based chemotherapy + ctla-4 inhibition + antifolate. indication: opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no egfr or alk genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + ipilimumab + paclitaxel + carboplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no egfr or alk genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "if a patient with colorectal adenocarcinoma has dmmr, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) colorectal cancer (crc) in combination with ipilimumab. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "if a patient with colorectal adenocarcinoma has msi-h, one recommended therapy is nivolumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "if a patient with colorectal adenocarcinoma has dmmr, one recommended therapy is nivolumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "if a patient with metastatic invasive breast carcinoma has er positive, her2-negative, pik3ca somatic variants, one recommended therapy is fulvestrant + palbociclib + inavolisib. therapy type: hormone therapy + targeted therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition + pi3k/akt/mtor inhibition. indication: itovebi is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, pik3ca-mutated, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer, as detected by an fda-approved test, following recurrence on or after completing adjuvant endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf", "if a patient with metastatic invasive breast carcinoma has pr positive, her2-negative, pik3ca somatic variants, one recommended therapy is fulvestrant + palbociclib + inavolisib. therapy type: hormone therapy + targeted therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition + pi3k/akt/mtor inhibition. indication: itovebi is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, pik3ca-mutated, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer, as detected by an fda-approved test, following recurrence on or after completing adjuvant endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf", "if a patient with metastatic invasive breast carcinoma has pr positive, er positive, her2-negative, pik3ca somatic variants, one recommended therapy is fulvestrant + palbociclib + inavolisib. therapy type: hormone therapy + targeted therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition + pi3k/akt/mtor inhibition. indication: itovebi is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, pik3ca-mutated, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer, as detected by an fda-approved test, following recurrence on or after completing adjuvant endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has cldn18.2 >= 75%, her2-negative, one recommended therapy is oxaliplatin + fluorouracil + zolbetuximab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + thymidylate synthase inhibition + cldn18.2 inhibition. indication: vyloy is a claudin 18.2-directed cytolytic antibody and is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (her2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (cldn) 18.2 positive as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has cldn18.2 >= 75%, her2-negative, one recommended therapy is capecitabine + oxaliplatin + zolbetuximab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + cldn18.2 inhibition. indication: vyloy is a claudin 18.2-directed cytolytic antibody and is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (her2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (cldn) 18.2 positive as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf", "if a patient with intraductal papillary neoplasm of the bile duct has her2-positive, one recommended therapy is zanidatamab. therapy type: targeted therapy. therapy strategy: er signaling inhibition. indication: zihera is a bispecific her2-directed antibody indicated for the treatment of adults with previously treated, unresectable or metastatic her2-positive (ihc 3+) biliary tract cancer (btc), as detected by an fda-approved test. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf", "if a patient with intracholecystic papillary neoplasm has her2-positive, one recommended therapy is zanidatamab. therapy type: targeted therapy. therapy strategy: er signaling inhibition. indication: zihera is a bispecific her2-directed antibody indicated for the treatment of adults with previously treated, unresectable or metastatic her2-positive (ihc 3+) biliary tract cancer (btc), as detected by an fda-approved test. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf", "if a patient with cholangiocarcinoma has her2-positive, one recommended therapy is zanidatamab. therapy type: targeted therapy. therapy strategy: er signaling inhibition. indication: zihera is a bispecific her2-directed antibody indicated for the treatment of adults with previously treated, unresectable or metastatic her2-positive (ihc 3+) biliary tract cancer (btc), as detected by an fda-approved test. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf", "if a patient with non-small cell lung cancer has v::nrg1, one recommended therapy is zenocutuzumab. therapy type: targeted therapy. therapy strategy: nrg1 inhibition. indication: bizengri is a bispecific her2- and her3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (nsclc) harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf", "if a patient with pancreatic adenocarcinoma has v::nrg1, one recommended therapy is zenocutuzumab. therapy type: targeted therapy. therapy strategy: nrg1 inhibition. indication: bizengri is a bispecific her2- and her3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is ensartinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: ensacove is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc) who have not previously received an alk-inhibitor. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf", "if a patient with metastatic colorectal adenocarcinoma has braf p.v600e, one recommended therapy is oxaliplatin + fluorouracil + cetuximab + encorafenib. therapy type: chemotherapy + chemotherapy + targeted therapy + targeted therapy. therapy strategy: platinum-based chemotherapy + thymidylate synthase inhibition + egfr inhibition + b-raf inhibition. indication: braftovi is a kinase inhibitor indicated in combination with cetuximab and mfolfox6, for the treatment of patients with metastatic colorectal cancer (mcrc) with a braf v600e mutation, as detected by an fda-approved test. this indication is approved under accelerated approval based on response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). braftovi is not indicated for treatment of patients with wild-type braf melanoma, wild-type braf crc, or wild-type braf nsclc. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ has bcr::abl1, one recommended therapy is asciminib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: scemblix is a kinase inhibitor indicated for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ has bcr::abl1, one recommended therapy is asciminib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: scemblix is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp). this indication is approved under accelerated approval based on major molecular response rate. continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf", "if a patient with metastatic non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + pemetrexed + carboplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: imjudo is a cytotoxic t-lymphocyte-associated antigen 4 (ctla-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutation or anaplastic lymphoma kinase (alk) genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf", "if a patient with metastatic non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + cisplatin + pemetrexed. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + platinum-based chemotherapy + antifolate. indication: imjudo is a cytotoxic t-lymphocyte-associated antigen 4 (ctla-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutation or anaplastic lymphoma kinase (alk) genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf", "if a patient with metastatic non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + gemcitabine + carboplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + antimetabolite + platinum-based chemotherapy. indication: imjudo is a cytotoxic t-lymphocyte-associated antigen 4 (ctla-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutation or anaplastic lymphoma kinase (alk) genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf", "if a patient with metastatic non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + cisplatin + gemcitabine. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + platinum-based chemotherapy + antimetabolite. indication: imjudo is a cytotoxic t-lymphocyte-associated antigen 4 (ctla-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutation or anaplastic lymphoma kinase (alk) genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf", "if a patient with metastatic non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + nab-paclitaxel + carboplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + taxane-based chemotherapy + platinum-based chemotherapy. indication: imjudo is a cytotoxic t-lymphocyte-associated antigen 4 (ctla-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutation or anaplastic lymphoma kinase (alk) genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf", "if a patient with acute lymphoid leukemia has t(kmt2a;v), one recommended therapy is revumenib. therapy type: targeted therapy. therapy strategy: menin inhibition. indication: revuforj is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2a gene (kmt2a) translocation in adult and pediatric patients 1 year and older. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218944s003lbl.pdf", "if a patient with acute myeloid leukemia has t(kmt2a;v), one recommended therapy is revumenib. therapy type: targeted therapy. therapy strategy: menin inhibition. indication: revuforj is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2a gene (kmt2a) translocation in adult and pediatric patients 1 year and older. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218944s003lbl.pdf", "if a patient with burkitt lymphoma has t(kmt2a;v), one recommended therapy is revumenib. therapy type: targeted therapy. therapy strategy: menin inhibition. indication: revuforj is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2a gene (kmt2a) translocation in adult and pediatric patients 1 year and older. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218944s003lbl.pdf", "if a patient with acute leukemias of ambiguous lineage has t(kmt2a;v), one recommended therapy is revumenib. therapy type: targeted therapy. therapy strategy: menin inhibition. indication: revuforj is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2a gene (kmt2a) translocation in adult and pediatric patients 1 year and older. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218944s003lbl.pdf", "if a patient with early invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is letrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with early invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is abemaciclib + anastrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with early invasive breast carcinoma has er positive, her2-negative, one recommended therapy is abemaciclib + anastrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with early invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is abemaciclib + anastrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with early invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is exemestane + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with early invasive breast carcinoma has er positive, her2-negative, one recommended therapy is exemestane + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with early invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is exemestane + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf", "if a patient with colorectal adenocarcinoma has msi-h, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) colorectal cancer (crc) in combination with ipilimumab. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "if a patient with non-small cell lung cancer has v::ros1, one recommended therapy is taletrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition + ros1 inhibition. indication: ibtrozi is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf", "if a patient with lung non-squamous non-small cell carcinoma has c-met >= 50%, one recommended therapy is telisotuzumab vedotin. therapy type: targeted therapy. therapy strategy: met inhibition. indication: emrelis is a c-met-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (nsclc) with high c-met protein overexpression [>=50% of tumor cells with strong (3+) staining], as determined by an fda-approved test, who have received a prior systemic therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf", "if a patient with low-grade serous ovarian cancer has kras p.g12c, one recommended therapy is avutometinib + defactinib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + raf inhibition + fak inhibition. indication: avmapki fakzynja co-pack, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with kras-mutated recurrent low-grade serous ovarian cancer (lgsoc) who have received prior systemic therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf", "if a patient with low-grade serous ovarian cancer has kras p.g12v, one recommended therapy is avutometinib + defactinib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + raf inhibition + fak inhibition. indication: avmapki fakzynja co-pack, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with kras-mutated recurrent low-grade serous ovarian cancer (lgsoc) who have received prior systemic therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf", "if a patient with low-risk apl with pml-rara has t(15;17), one recommended therapy is arsenic trioxide. therapy type: targeted therapy. therapy strategy: pml::rara inhibition. indication: trisenox is an arsenical indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (apl) whose apl is characterized by the presence of the t(15;17) translocation or pml/rar-alpha gene expression. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf", "if a patient with apl with pml-rara has t(15;17), one recommended therapy is arsenic trioxide. therapy type: targeted therapy. therapy strategy: pml::rara inhibition. indication: trisenox is an arsenical indicated for induction of remission and consolidation in patients with apl who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterized by the presence of the t(15;17) translocation or pml/rar-alpha gene expression. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is nilotinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: tasigna is a kinase inhibitor indicated for the treatment of pediatric patients greater than or equal to 1 year of age with ph+ cml-cp and cml-ap resistant or intolerant to prior tyrosine-kinase inhibitor (tki) therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf", "if a patient with chronic myeloid leukemia, bcr-abl1+ has bcr::abl1, one recommended therapy is nilotinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: tasigna is a kinase inhibitor indicated for the treatment of pediatric patients greater than or equal to 1 year of age with ph+ cml-cp and cml-ap resistant or intolerant to prior tyrosine-kinase inhibitor (tki) therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf", "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia has bcr::abl1, one recommended therapy is asciminib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: scemblix is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp). this indication is approved under accelerated approval based on major molecular response rate. continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf", "if a patient with head and neck squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult patients with locally advanced hnscc whose tumors express pd-l1 [combined positive score (cps) >= 1] as determined by an fda-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (rt), with or without cisplatin and then as a single agent. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf", "if a patient with non-small cell lung cancer has egfr somatic variants, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf", "if a patient with non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf", "if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf", "if a patient with non-small cell lung cancer has egfr p.t790m, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf", "if a patient with invasive breast carcinoma has egfr exon 20 (insertion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf", "if a patient with invasive breast carcinoma has er positive, her2-negative, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf", "if a patient with non-small cell lung cancer has pr positive, her2-negative, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf", "if a patient with invasive breast carcinoma has pr positive, er positive, her2-negative, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf", "if a patient with non-small cell lung cancer has egfr exon 20 (insertion), one recommended therapy is sunvozertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition + her2 inhibition. indication: zegfrovy is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 insertion mutations, as detected by an fda-approved test, whose disease has progressed on or after platinum-based chemotherapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219839s000lbl.pdf", "if a patient with lung non-squamous non-small cell carcinoma has erbb2 tkd activating variants, one recommended therapy is zongertinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: hernexeos is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (nsclc) whose tumors have her2 (erbb2) tyrosine kinase domain activating mutations, as detected by an fda-approved test, and who have received prior systemic therapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219042s000lbl.pdf", "if a patient with diffuse midline glioma has h3-3a p.k27m, one recommended therapy is dordaviprone. therapy type: targeted therapy. therapy strategy: protease activation. indication: modeyso is a protease activator indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an h3 k27m mutation with progressive disease following prior therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219876s000lbl.pdf", "if a patient with invasive breast carcinoma has esr1 oncogenic variants, er positive, her2-negative, one recommended therapy is imlunestrant. therapy type: targeted therapy. therapy strategy: estrogen receptor inhibition. indication: inluriyo is an estrogen receptor antagonist indicated for treatment of adults with er-positive, her2-negative, esr1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218881s000lbl.pdf", "if a patient with unresectable or metastatic colorectal adenocarcinoma has her2-positive, wild type nras, wild type kras, one recommended therapy is trastuzumab + tucatinib. therapy type: targeted therapy + targeted therapy. therapy strategy: her2 inhibition + her2 inhibition. indication: tukysa is a kinase inhibitor indicated in combination with trastuzumab for the treatment of adult patients with ras wild-type her2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. this indication is approved under accelerated approval based on tumor response rate and durability of response [see clinical studies (14.2)]. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf", "if a patient with acute myeloid leukemia has flt3-itd, one recommended therapy is quizartinib. therapy type: targeted therapy. therapy strategy: flt3 inhibition. indication: vanflyta is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 internal tandem duplication (itd)-positive as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216993s001lbl.pdf", "if a patient with acute myeloid leukemia has flt3-itd, one recommended therapy is quizartinib + daunorubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + topoisomerase inhibition + dna polymerase inhibition. indication: vanflyta is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 internal tandem duplication (itd)-positive as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216993s001lbl.pdf", "if a patient with acute myeloid leukemia has flt3-itd, one recommended therapy is quizartinib + idarubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + topoisomerase inhibition + dna polymerase inhibition. indication: vanflyta is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 internal tandem duplication (itd)-positive as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216993s001lbl.pdf", "if a patient with melanoma has braf p.v600e, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "if a patient with melanoma has braf p.v600k, one recommended therapy is dabrafenib + trametinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "if a patient with chronic lymphocytic leukemia has 17p deletion, one recommended therapy is ibrutinib. therapy type: targeted therapy. therapy strategy: btk inhibition. indication: imbruvica is a kinase inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) / small lymphocytic lymphoma (sll) with 17p deletion. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205552s043,210563s019,217003s004lbl.pdf", "if a patient with acute myeloid leukemia has npm1 p.w288cfs*12, one recommended therapy is ziftomenib. therapy type: targeted therapy. therapy strategy: menin inhibition. indication: komzifti is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with a susceptible nucleophosmin 1 (npm1) mutation who have no satisfactory alterantive treatment options. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220305s000lbl.pdf", "if a patient with lung non-squamous non-small cell carcinoma has erbb2 tkd activating variants, one recommended therapy is sevabertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition + her2 inhibition. indication: hyrnuo is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (nsclc) whose tumors have her2 (erbb2) tyrosine kinase domain (tkd) activating mutations, as detected by an fda-approved test, and who have received prior systemic therapy. this indication is approved under accelerated approval based on objective response rate (orr) and duration of response (dor). continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219972s000lblCorrected.pdf", "if a patient with unresectable or metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab deruxtecan + pertuzumab. therapy type: targeted therapy + targeted therapy. therapy strategy: her2 inhibition + her2 inhibition. indication: enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated in combination with pertuzumab as first-line treatment of adult patients with unresectable or metastatic her2-positive (ihc 3+ or ish+) breast cancer, as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf", "if a patient with acute myeloid leukemia has npm1 p.w288cfs*12, one recommended therapy is revumenib. therapy type: targeted therapy. therapy strategy: menin inhibition. indication: revuforj is a menin inhibitor indicated for the treatment of relapsed or refractory acute myeloid leukemia (aml) with a susceptible nucleophosmin 1 (npm1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218944s003lbl.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 (tap) >= 1%, one recommended therapy is fluorouracil + cisplatin + tislelizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (escc) whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 (tap) >= 1%, one recommended therapy is capecitabine + cisplatin + tislelizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (escc) whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 (tap) >= 1%, one recommended therapy is oxaliplatin + fluorouracil + tislelizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (escc) whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 (tap) >= 1%, one recommended therapy is capecitabine + oxaliplatin + tislelizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (escc) whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 (tap) >= 1%, one recommended therapy is cisplatin + tislelizumab + paclitaxel. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition + taxane-based chemotherapy. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (escc) whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 (tap) >= 1%, one recommended therapy is oxaliplatin + tislelizumab + paclitaxel. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition + taxane-based chemotherapy. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (escc) whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is fluorouracil + cisplatin + tislelizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (escc) whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is capecitabine + cisplatin + tislelizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (escc) whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is oxaliplatin + fluorouracil + tislelizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (escc) whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is capecitabine + oxaliplatin + tislelizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (escc) whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is cisplatin + tislelizumab + paclitaxel. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition + taxane-based chemotherapy. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (escc) whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is oxaliplatin + tislelizumab + paclitaxel. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition + taxane-based chemotherapy. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (escc) whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has pd-l1 (tap) >= 1%, her2-negative, one recommended therapy is capecitabine + oxaliplatin + tislelizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic her2-negative gastric or gastroesophageal junction adenocracinoma whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has pd-l1 (tap) >= 1%, her2-negative, one recommended therapy is fluorouracil + cisplatin + tislelizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic her2-negative gastric or gastroesophageal junction adenocracinoma whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has pd-l1 (cps) >= 1, her2-negative, one recommended therapy is capecitabine + oxaliplatin + tislelizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic her2-negative gastric or gastroesophageal junction adenocracinoma whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has pd-l1 (cps) >= 1, her2-negative, one recommended therapy is fluorouracil + cisplatin + tislelizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: tevimbra is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic her2-negative gastric or gastroesophageal junction adenocracinoma whose tumors express pd-l1 (>=1). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf", "if a patient with acute lymphoid leukemia has npm1 p.w288cfs*12, one recommended therapy is revumenib. therapy type: targeted therapy. therapy strategy: menin inhibition. indication: revuforj is a menin inhibitor indicated for the treatment of relapsed or refractory acute myeloid leukemia (aml) with a susceptible nucleophosmin 1 (npm1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218944s003lbl.pdf", "if a patient with burkitt lymphoma has npm1 p.w288cfs*12, one recommended therapy is revumenib. therapy type: targeted therapy. therapy strategy: menin inhibition. indication: revuforj is a menin inhibitor indicated for the treatment of relapsed or refractory acute myeloid leukemia (aml) with a susceptible nucleophosmin 1 (npm1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218944s003lbl.pdf", "if a patient with acute leukemias of ambiguous lineage has npm1 p.w288cfs*12, one recommended therapy is revumenib. therapy type: targeted therapy. therapy strategy: menin inhibition. indication: revuforj is a menin inhibitor indicated for the treatment of relapsed or refractory acute myeloid leukemia (aml) with a susceptible nucleophosmin 1 (npm1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218944s003lbl.pdf"]